https://trial.medpath.com/news/first-sars-cov-2-exposure-shapes-igg-subclass-switching-and-breakthrough-infection-risk-after-mrna-vaccination 2026-06-24T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-sars-cov-2-exposure-shapes-igg-subclass-switching-and-breakthrough-infection-risk-after-mrna-vaccination 2026-06-24T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/celecor-completes-fda-submission-for-zalunfiban-a-first-point-of-care-antiplatelet-for-stemi-heart-attacks 2026-06-24T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celecor-completes-fda-submission-for-zalunfiban-a-first-point-of-care-antiplatelet-for-stemi-heart-attacks 2026-06-24T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/institute-for-autism-research-relocates-to-university-at-buffalo-with-450000-grant-expanding-access-to-evidence-based-social-skills-programs 2026-06-24T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/institute-for-autism-research-relocates-to-university-at-buffalo-with-450000-grant-expanding-access-to-evidence-based-social-skills-programs 2026-06-24T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/stripe-anthropic-and-openai-back-500-million-intercept-fund-to-eliminate-respiratory-viruses 2026-06-24T16:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stripe-anthropic-and-openai-back-500-million-intercept-fund-to-eliminate-respiratory-viruses 2026-06-24T16:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-therapeutics-files-for-chapter-11-bankruptcy-eli-lilly-and-astellas-positioned-as-lead-bidders-for-key-assets 2026-06-24T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-therapeutics-files-for-chapter-11-bankruptcy-eli-lilly-and-astellas-positioned-as-lead-bidders-for-key-assets 2026-06-24T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/nature-medicine-retracts-controversial-phase-3-trial-on-time-of-day-immunochemotherapy-in-nsclc 2026-06-24T16:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-medicine-retracts-controversial-phase-3-trial-on-time-of-day-immunochemotherapy-in-nsclc 2026-06-24T16:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/megacluster-of-antibiotic-genes-discovered-in-soil-bacteria-targets-biotin-pathway-to-combat-superbugs 2026-06-24T16:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/megacluster-of-antibiotic-genes-discovered-in-soil-bacteria-targets-biotin-pathway-to-combat-superbugs 2026-06-24T16:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/investigational-ctsa-inhibitor-offers-new-pathway-for-cholesterol-control-study-in-nature-reveals 2026-06-24T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investigational-ctsa-inhibitor-offers-new-pathway-for-cholesterol-control-study-in-nature-reveals 2026-06-24T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/hkeybio-launches-hkey-exetm-1-0-preclinical-framework-to-accelerate-drug-development-for-eosinophilic-gastrointestinal-disorders 2026-06-24T15:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkeybio-launches-hkey-exetm-1-0-preclinical-framework-to-accelerate-drug-development-for-eosinophilic-gastrointestinal-disorders 2026-06-24T15:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/reprocell-submits-application-for-stem-cell-therapy-stemchymal-in-japan-for-spinocerebellar-ataxia-sca3-and-sca6 2026-06-24T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reprocell-submits-application-for-stem-cell-therapy-stemchymal-in-japan-for-spinocerebellar-ataxia-sca3-and-sca6 2026-06-24T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/ehu-researchers-develop-novel-metabolomics-protocol-to-identify-sperm-biomarkers-for-male-infertility-diagnosis 2026-06-24T14:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ehu-researchers-develop-novel-metabolomics-protocol-to-identify-sperm-biomarkers-for-male-infertility-diagnosis 2026-06-24T14:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/imbria-s-ninerafaxstat-wins-fda-orphan-drug-designation-for-non-obstructive-hypertrophic-cardiomyopathy 2026-06-24T14:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imbria-s-ninerafaxstat-wins-fda-orphan-drug-designation-for-non-obstructive-hypertrophic-cardiomyopathy 2026-06-24T14:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/ollin-biosciences-secures-330m-series-b-to-advance-vabysmo-challenger-into-phase-3-trials 2026-06-24T14:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ollin-biosciences-secures-330m-series-b-to-advance-vabysmo-challenger-into-phase-3-trials 2026-06-24T14:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimer-s-disease-testing 2026-06-24T14:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimer-s-disease-testing 2026-06-24T14:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-researchers-identify-three-distinct-biological-subtypes-of-severe-pneumonia-explaining-variable-icu-outcomes 2026-06-24T14:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-researchers-identify-three-distinct-biological-subtypes-of-severe-pneumonia-explaining-variable-icu-outcomes 2026-06-24T14:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-becoming-rentable-partner-to-expand-accessible-short-term-rentals-for-the-sma-community 2026-06-24T14:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-and-becoming-rentable-partner-to-expand-accessible-short-term-rentals-for-the-sma-community 2026-06-24T14:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/waters-and-imu-biosciences-forge-strategic-partnership-to-scale-ai-powered-immune-mapping-platform 2026-06-24T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-and-imu-biosciences-forge-strategic-partnership-to-scale-ai-powered-immune-mapping-platform 2026-06-24T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/hidden-lung-specific-dpp9-protein-variant-linked-to-severe-covid-19-and-lung-fibrosis 2026-06-24T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hidden-lung-specific-dpp9-protein-variant-linked-to-severe-covid-19-and-lung-fibrosis 2026-06-24T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-and-duopharma-biotech-secure-over-myr-225-million-in-insulin-contracts-from-malaysia-s-ministry-of-health 2026-06-24T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-and-duopharma-biotech-secure-over-myr-225-million-in-insulin-contracts-from-malaysia-s-ministry-of-health 2026-06-24T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/antares-therapeutics-signs-potential-1-9-billion-deal-with-novartis-to-target-undruggable-oncology-proteins 2026-06-24T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antares-therapeutics-signs-potential-1-9-billion-deal-with-novartis-to-target-undruggable-oncology-proteins 2026-06-24T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/60-years-of-austrian-newborn-screening-early-detection-transforming-outcomes-for-thousands-of-children 2026-06-24T12:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/60-years-of-austrian-newborn-screening-early-detection-transforming-outcomes-for-thousands-of-children 2026-06-24T12:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/thalia-acquires-sanmirna-secures-ps2-75m-to-advance-anti-mirna-therapy-for-aml 2026-06-24T12:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thalia-acquires-sanmirna-secures-ps2-75m-to-advance-anti-mirna-therapy-for-aml 2026-06-24T12:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/hierarchical-endpoints-and-win-statistics-a-paradigm-shift-for-geromedicine-clinical-trials 2026-06-24T12:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hierarchical-endpoints-and-win-statistics-a-paradigm-shift-for-geromedicine-clinical-trials 2026-06-24T12:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacovigilance-automation-market-to-reach-usd-5-25-billion-by-2035-driven-by-ai-and-nlp-adoption 2026-06-24T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacovigilance-automation-market-to-reach-usd-5-25-billion-by-2035-driven-by-ai-and-nlp-adoption 2026-06-24T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-moves-beyond-diagnosis-to-prognostic-and-predictive-applications-in-precision-oncology 2026-06-24T11:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pet-imaging-moves-beyond-diagnosis-to-prognostic-and-predictive-applications-in-precision-oncology 2026-06-24T11:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/microbiome-therapeutics-market-poised-to-surge-from-288-8m-to-4b-by-2034-driven-by-defined-consortia-and-immuno-oncology-innovations 2026-06-24T11:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiome-therapeutics-market-poised-to-surge-from-288-8m-to-4b-by-2034-driven-by-defined-consortia-and-immuno-oncology-innovations 2026-06-24T11:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-and-hainan-herui-forge-commercialization-partnership-for-budesonide-enteric-capsules-in-china 2026-06-24T11:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-and-hainan-herui-forge-commercialization-partnership-for-budesonide-enteric-capsules-in-china 2026-06-24T11:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-with-rituximab-may-temporarily-restore-fertility-in-autoimmune-premature-ovarian-insufficiency 2026-06-24T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-with-rituximab-may-temporarily-restore-fertility-in-autoimmune-premature-ovarian-insufficiency 2026-06-24T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-cancer-disparities-progress-report-2026-reveals-narrowing-gaps-but-persistent-inequities-across-u-s-populations 2026-06-24T10:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aacr-cancer-disparities-progress-report-2026-reveals-narrowing-gaps-but-persistent-inequities-across-u-s-populations 2026-06-24T10:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/tesamorelin-the-fda-approved-ghrh-analog-bridging-clinical-certainty-and-research-frontiers 2026-06-24T10:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tesamorelin-the-fda-approved-ghrh-analog-bridging-clinical-certainty-and-research-frontiers 2026-06-24T10:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-premarket-approval-to-hepquant-shunt-liver-diagnostic-test-for-compensated-cirrhosis 2026-06-24T09:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-premarket-approval-to-hepquant-shunt-liver-diagnostic-test-for-compensated-cirrhosis 2026-06-24T09:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/doj-s-2026-health-care-fraud-takedown-455-charged-6-5-billion-in-alleged-false-claims-signals-new-era-of-data-driven-enforcement 2026-06-24T09:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doj-s-2026-health-care-fraud-takedown-455-charged-6-5-billion-in-alleged-false-claims-signals-new-era-of-data-driven-enforcement 2026-06-24T09:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/rq-bio-secures-115-million-series-a-to-advance-long-acting-antibody-rqb01-for-full-season-influenza-prevention 2026-06-24T09:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rq-bio-secures-115-million-series-a-to-advance-long-acting-antibody-rqb01-for-full-season-influenza-prevention 2026-06-24T09:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/extracellular-vesicles-as-next-generation-therapeutics-global-pipeline-regulatory-landscape-and-translational-challenges 2026-06-24T09:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extracellular-vesicles-as-next-generation-therapeutics-global-pipeline-regulatory-landscape-and-translational-challenges 2026-06-24T09:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/gata6-loss-unlocks-a-hidden-switch-driving-colorectal-cancer-liver-metastasis 2026-06-24T09:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gata6-loss-unlocks-a-hidden-switch-driving-colorectal-cancer-liver-metastasis 2026-06-24T09:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/phathom-completes-enrollment-ahead-of-schedule-in-landmark-phase-2-trial-of-vonoprazan-for-eosinophilic-esophagitis 2026-06-24T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phathom-completes-enrollment-ahead-of-schedule-in-landmark-phase-2-trial-of-vonoprazan-for-eosinophilic-esophagitis 2026-06-24T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-typographical-error-in-provisional-application-spoils-priority-date-invalidating-enanta-patent-against-pfizer-s-paxlovid 2026-06-24T08:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-rules-typographical-error-in-provisional-application-spoils-priority-date-invalidating-enanta-patent-against-pfizer-s-paxlovid 2026-06-24T08:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/first-hand-account-chemotherapy-and-immunotherapy-infusion-begins-at-queen-s-cancer-center 2026-06-24T08:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-hand-account-chemotherapy-and-immunotherapy-infusion-begins-at-queen-s-cancer-center 2026-06-24T08:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/florida-attorney-general-launches-anticompetitive-investigation-into-cvs-caremark-over-pharmacy-practices 2026-06-24T08:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-attorney-general-launches-anticompetitive-investigation-into-cvs-caremark-over-pharmacy-practices 2026-06-24T08:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-etf-technical-analysis-ibb-and-pbe-show-strong-sentiment-across-all-horizons 2026-06-24T08:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-etf-technical-analysis-ibb-and-pbe-show-strong-sentiment-across-all-horizons 2026-06-24T08:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/blow-fill-seal-technology-market-poised-to-reach-6-95-billion-by-2030-driven-by-sterile-pharmaceutical-packaging-demand 2026-06-24T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blow-fill-seal-technology-market-poised-to-reach-6-95-billion-by-2030-driven-by-sterile-pharmaceutical-packaging-demand 2026-06-24T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/voyageur-pharmaceuticals-engages-fluor-for-feasibility-studies-on-north-america-s-first-vertically-integrated-contrast-media-supply-chain 2026-06-24T07:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyageur-pharmaceuticals-engages-fluor-for-feasibility-studies-on-north-america-s-first-vertically-integrated-contrast-media-supply-chain 2026-06-24T07:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/netec-announces-second-round-of-nsps-level-2-stand-awards-expanding-special-pathogen-preparedness-to-75-u-s-facilities 2026-06-24T07:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/netec-announces-second-round-of-nsps-level-2-stand-awards-expanding-special-pathogen-preparedness-to-75-u-s-facilities 2026-06-24T07:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-aft-pharmaceuticals-injectable-iron-project-to-proceed-to-global-phase-3-trial 2026-06-24T05:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-aft-pharmaceuticals-injectable-iron-project-to-proceed-to-global-phase-3-trial 2026-06-24T05:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-patient-detoxes-from-130-pill-a-day-opioid-addiction-in-20-minutes-using-noninvasive-focused-ultrasound-neuromodulation 2026-06-24T05:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israeli-patient-detoxes-from-130-pill-a-day-opioid-addiction-in-20-minutes-using-noninvasive-focused-ultrasound-neuromodulation 2026-06-24T05:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunotherapy-shows-promise-as-bridge-to-liver-transplant-in-hcc-but-rejection-risk-demands-caution 2026-06-24T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-shows-promise-as-bridge-to-liver-transplant-in-hcc-but-rejection-risk-demands-caution 2026-06-24T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/prior-authorization-delays-linked-to-worsened-outcomes-in-neurological-diseases-study-finds 2026-06-24T02:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prior-authorization-delays-linked-to-worsened-outcomes-in-neurological-diseases-study-finds 2026-06-24T02:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/corxel-s-oral-glp-1-agonist-cx11-achieves-up-to-11-5-weight-loss-in-u-s-phase-2-obesity-trial 2026-06-24T01:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corxel-s-oral-glp-1-agonist-cx11-achieves-up-to-11-5-weight-loss-in-u-s-phase-2-obesity-trial 2026-06-24T01:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/grammy-winning-singer-muni-long-receives-life-saving-double-lung-transplant-after-one-week-prognosis 2026-06-24T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grammy-winning-singer-muni-long-receives-life-saving-double-lung-transplant-after-one-week-prognosis 2026-06-24T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-t-cells-with-novel-pd-l1-specific-tcr-target-both-cancer-and-immunosuppressive-immune-cells 2026-06-24T01:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-t-cells-with-novel-pd-l1-specific-tcr-target-both-cancer-and-immunosuppressive-immune-cells 2026-06-24T01:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-partners-with-alcedis-to-advance-clinical-research-using-wearable-based-endpoints 2026-06-24T00:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-partners-with-alcedis-to-advance-clinical-research-using-wearable-based-endpoints 2026-06-24T00:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/ups-invests-48-million-in-global-cold-chain-expansion-to-meet-surging-biologics-demand 2026-06-24T00:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ups-invests-48-million-in-global-cold-chain-expansion-to-meet-surging-biologics-demand 2026-06-24T00:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/piezo1-the-mechanosensitive-ion-channel-at-the-crossroads-of-bone-health-and-orthopedic-disease 2026-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piezo1-the-mechanosensitive-ion-channel-at-the-crossroads-of-bone-health-and-orthopedic-disease 2026-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-lactate-lactylation-axis-in-tumor-radioresistance-from-metabolic-adaptation-to-therapeutic-targeting 2026-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-lactate-lactylation-axis-in-tumor-radioresistance-from-metabolic-adaptation-to-therapeutic-targeting 2026-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gaba-immune-pathway-drives-sex-specific-glioblastoma-growth-in-females-study-finds 2026-06-23T23:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gaba-immune-pathway-drives-sex-specific-glioblastoma-growth-in-females-study-finds 2026-06-23T23:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-and-zumutor-launch-phase-1-trial-of-nk-checkpoint-antibody-zm008-combined-with-pd-1-inhibitor-loqtorzi-in-solid-tumors 2026-06-23T23:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-and-zumutor-launch-phase-1-trial-of-nk-checkpoint-antibody-zm008-combined-with-pd-1-inhibitor-loqtorzi-in-solid-tumors 2026-06-23T23:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/market-rotation-fuels-biotech-surge-as-ai-trade-falters-definium-therapeutics-rises-on-anxiety-disorder-catalyst 2026-06-23T23:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/market-rotation-fuels-biotech-surge-as-ai-trade-falters-definium-therapeutics-rises-on-anxiety-disorder-catalyst 2026-06-23T23:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/pathway-labs-echonext-receives-world-s-first-fda-clearance-for-ai-detection-of-hidden-structural-heart-disease-from-routine-ecgs 2026-06-23T22:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathway-labs-echonext-receives-world-s-first-fda-clearance-for-ai-detection-of-hidden-structural-heart-disease-from-routine-ecgs 2026-06-23T22:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/zhenjiankang-medical-s-ipo-surge-how-a-percutaneous-surgical-robotics-pioneer-achieved-three-accelerations-in-eight-years 2026-06-23T22:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhenjiankang-medical-s-ipo-surge-how-a-percutaneous-surgical-robotics-pioneer-achieved-three-accelerations-in-eight-years 2026-06-23T22:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/va-greater-los-angeles-healthcare-system-celebrates-national-va-research-week-2026-honors-pioneering-researchers 2026-06-23T22:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/va-greater-los-angeles-healthcare-system-celebrates-national-va-research-week-2026-honors-pioneering-researchers 2026-06-23T22:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/agomab-unveils-design-for-first-ever-phase-2b-trial-in-fibrostenosing-crohn-s-disease-with-oral-alk5-inhibitor-ontunisertib 2026-06-23T21:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agomab-unveils-design-for-first-ever-phase-2b-trial-in-fibrostenosing-crohn-s-disease-with-oral-alk5-inhibitor-ontunisertib 2026-06-23T21:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/mosquitoes-test-positive-for-west-nile-virus-in-bernalillo-county-new-mexico 2026-06-23T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosquitoes-test-positive-for-west-nile-virus-in-bernalillo-county-new-mexico 2026-06-23T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/slope-and-velocity-clinical-research-partner-to-standardize-inventory-management-across-70-sites 2026-06-23T20:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/slope-and-velocity-clinical-research-partner-to-standardize-inventory-management-across-70-sites 2026-06-23T20:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/tcr-engineered-t-cells-targeting-shared-b-catenin-mutation-eradicate-solid-tumors-earns-ous-research-prize 2026-06-23T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tcr-engineered-t-cells-targeting-shared-b-catenin-mutation-eradicate-solid-tumors-earns-ous-research-prize 2026-06-23T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-medicine-in-oncology-experts-call-for-patient-centered-innovation-and-better-communication-at-islb-and-asco-meetings 2026-06-23T19:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-medicine-in-oncology-experts-call-for-patient-centered-innovation-and-better-communication-at-islb-and-asco-meetings 2026-06-23T19:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-files-amicus-brief-supporting-antitrust-suit-against-johnson-johnson-over-stelara-monopoly 2026-06-23T19:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-files-amicus-brief-supporting-antitrust-suit-against-johnson-johnson-over-stelara-monopoly 2026-06-23T19:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-led-consortium-launches-billion-cellxcell-project-to-decode-cellular-communication-published-in-nature-biotechnology 2026-06-23T19:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-led-consortium-launches-billion-cellxcell-project-to-decode-cellular-communication-published-in-nature-biotechnology 2026-06-23T19:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/seegnal-to-deploy-medication-safety-platform-at-nazareth-hospital-emms-targeting-alert-fatigue-in-clinical-prescribing 2026-06-23T18:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seegnal-to-deploy-medication-safety-platform-at-nazareth-hospital-emms-targeting-alert-fatigue-in-clinical-prescribing 2026-06-23T18:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/local-access-to-radiation-oncology-strengthens-cancer-care-in-the-quad-cities-as-iowa-faces-rising-cancer-rates 2026-06-23T18:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/local-access-to-radiation-oncology-strengthens-cancer-care-in-the-quad-cities-as-iowa-faces-rising-cancer-rates 2026-06-23T18:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/masshealth-to-end-glp-1-coverage-for-weight-loss-affecting-22000-patients 2026-06-23T18:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/masshealth-to-end-glp-1-coverage-for-weight-loss-affecting-22000-patients 2026-06-23T18:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/leal-therapeutics-secures-30-million-series-a-extension-and-initiates-phase-1b-2a-trial-of-ltx-001-in-schizophrenia 2026-06-23T18:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leal-therapeutics-secures-30-million-series-a-extension-and-initiates-phase-1b-2a-trial-of-ltx-001-in-schizophrenia 2026-06-23T18:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-dominates-q1-2025-branded-pharma-earnings-with-55-5-revenue-surge-merck-supernus-post-mixed-results 2026-06-23T18:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-dominates-q1-2025-branded-pharma-earnings-with-55-5-revenue-surge-merck-supernus-post-mixed-results 2026-06-23T18:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-canada-and-sp-quebec-mark-16-years-of-partnership-with-ms-tri-challenge-surpassing-650000-cad-in-fundraising 2026-06-23T18:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-canada-and-sp-quebec-mark-16-years-of-partnership-with-ms-tri-challenge-surpassing-650000-cad-in-fundraising 2026-06-23T18:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-signs-up-to-3-2-billion-option-and-licensing-deal-with-novartis-for-subcutaneous-formulations 2026-06-23T18:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alteogen-signs-up-to-3-2-billion-option-and-licensing-deal-with-novartis-for-subcutaneous-formulations 2026-06-23T18:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/whole-genome-sequencing-maps-rpob-mutations-that-predict-rifabutin-susceptibility-in-multidrug-resistant-tuberculosis 2026-06-23T18:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whole-genome-sequencing-maps-rpob-mutations-that-predict-rifabutin-susceptibility-in-multidrug-resistant-tuberculosis 2026-06-23T18:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-developer-sangamo-therapeutics-files-for-chapter-11-bankruptcy-with-sale-plans 2026-06-23T18:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-developer-sangamo-therapeutics-files-for-chapter-11-bankruptcy-with-sale-plans 2026-06-23T18:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/ichnos-glenmark-innovation-appoints-mariana-cota-stirner-as-chief-medical-officer-to-advance-multispecific-antibody-pipeline 2026-06-23T18:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ichnos-glenmark-innovation-appoints-mariana-cota-stirner-as-chief-medical-officer-to-advance-multispecific-antibody-pipeline 2026-06-23T18:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ide-approval-for-solenic-medical-s-sola-2-pivotal-trial-in-periprosthetic-joint-infections 2026-06-23T18:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ide-approval-for-solenic-medical-s-sola-2-pivotal-trial-in-periprosthetic-joint-infections 2026-06-23T18:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/veristat-bolsters-leadership-with-four-strategic-hires-to-accelerate-novel-therapy-approvals-in-cell-and-gene-therapy-oncology-and-rare-disease 2026-06-23T18:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veristat-bolsters-leadership-with-four-strategic-hires-to-accelerate-novel-therapy-approvals-in-cell-and-gene-therapy-oncology-and-rare-disease 2026-06-23T18:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/meet-the-doctor-building-tiny-tools-for-big-science-breakthroughs-ucla-s-steven-jonas-on-nanotechnology-pediatric-cancer-and-the-future-of-cell-and-gene-therapy 2026-06-23T18:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meet-the-doctor-building-tiny-tools-for-big-science-breakthroughs-ucla-s-steven-jonas-on-nanotechnology-pediatric-cancer-and-the-future-of-cell-and-gene-therapy 2026-06-23T18:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/unapproved-klotho-gene-therapy-for-longevity-set-to-launch-at-offshore-clinics-raising-safety-and-ethics-concerns 2026-06-23T18:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unapproved-klotho-gene-therapy-for-longevity-set-to-launch-at-offshore-clinics-raising-safety-and-ethics-concerns 2026-06-23T18:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/tetanus-cases-rise-in-the-u-s-amid-declining-vaccination-rates-cdc-reports-show 2026-06-23T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tetanus-cases-rise-in-the-u-s-amid-declining-vaccination-rates-cdc-reports-show 2026-06-23T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/engaging-families-in-hie-research-a-call-to-action-for-neonatal-care-and-drug-development 2026-06-23T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engaging-families-in-hie-research-a-call-to-action-for-neonatal-care-and-drug-development 2026-06-23T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/cognivia-and-mayo-clinic-collaborate-to-advance-behavioral-intelligence-in-clinical-research-and-patient-care 2026-06-23T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognivia-and-mayo-clinic-collaborate-to-advance-behavioral-intelligence-in-clinical-research-and-patient-care 2026-06-23T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researcher-wins-5-6m-nih-avant-garde-award-to-develop-ai-tools-for-hiv-hepatitis-c-and-overdose-prevention 2026-06-23T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-researcher-wins-5-6m-nih-avant-garde-award-to-develop-ai-tools-for-hiv-hepatitis-c-and-overdose-prevention 2026-06-23T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/europe-positions-itself-as-global-science-superpower-amid-us-research-turmoil 2026-06-23T16:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/europe-positions-itself-as-global-science-superpower-amid-us-research-turmoil 2026-06-23T16:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-saturnus-bio-with-versant-ventures-in-50m-build-to-buy-deal-targeting-rare-genetic-cardiomyopathies 2026-06-23T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-launches-saturnus-bio-with-versant-ventures-in-50m-build-to-buy-deal-targeting-rare-genetic-cardiomyopathies 2026-06-23T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-biomendics-tolasure-gel-for-epidermolysis-bullosa-simplex 2026-06-23T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-biomendics-tolasure-gel-for-epidermolysis-bullosa-simplex 2026-06-23T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/understanding-anthrax-expert-insights-on-transmission-treatment-and-prevention-of-a-persistent-zoonotic-threat 2026-06-23T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/understanding-anthrax-expert-insights-on-transmission-treatment-and-prevention-of-a-persistent-zoonotic-threat 2026-06-23T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/canary-speech-launches-ai-powered-vocal-biomarker-tool-on-zoom-app-marketplace-for-real-time-behavioral-and-cognitive-health-screening 2026-06-23T16:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canary-speech-launches-ai-powered-vocal-biomarker-tool-on-zoom-app-marketplace-for-real-time-behavioral-and-cognitive-health-screening 2026-06-23T16:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/wheeler-bio-launches-redesigned-website-showcasing-expanded-integrated-cdmo-capabilities-and-ai-ml-enabled-modularcmctm-platform 2026-06-23T16:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wheeler-bio-launches-redesigned-website-showcasing-expanded-integrated-cdmo-capabilities-and-ai-ml-enabled-modularcmctm-platform 2026-06-23T16:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/time-toxicity-in-lymphoma-study-reveals-stark-differences-in-treatment-burden-among-bispecific-antibodies 2026-06-23T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/time-toxicity-in-lymphoma-study-reveals-stark-differences-in-treatment-burden-among-bispecific-antibodies 2026-06-23T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/american-lung-association-launches-campaign-to-educate-patients-on-expanded-access-programs-for-investigational-lung-disease-treatments 2026-06-23T16:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-lung-association-launches-campaign-to-educate-patients-on-expanded-access-programs-for-investigational-lung-disease-treatments 2026-06-23T16:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-launches-ai-powered-virtual-screening-platform-that-predicts-gpcr-drug-mechanism-of-action 2026-06-23T15:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandboxaq-launches-ai-powered-virtual-screening-platform-that-predicts-gpcr-drug-mechanism-of-action 2026-06-23T15:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/nvidia-launches-bionemo-agent-toolkit-to-bring-agentic-ai-to-life-sciences-r-d 2026-06-23T15:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nvidia-launches-bionemo-agent-toolkit-to-bring-agentic-ai-to-life-sciences-r-d 2026-06-23T15:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/oligonucleotide-synthesis-market-to-reach-8-6-billion-by-2035-driven-by-therapeutic-pipeline-expansion-and-crispr-adoption 2026-06-23T15:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oligonucleotide-synthesis-market-to-reach-8-6-billion-by-2035-driven-by-therapeutic-pipeline-expansion-and-crispr-adoption 2026-06-23T15:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-healthcare-risks-encoding-and-amplifying-health-inequities-experts-warn 2026-06-23T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-in-healthcare-risks-encoding-and-amplifying-health-inequities-experts-warn 2026-06-23T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/joseph-balthasar-pioneer-in-antibody-drug-conjugate-and-protein-therapeutics-research-named-suny-distinguished-professor 2026-06-23T14:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/joseph-balthasar-pioneer-in-antibody-drug-conjugate-and-protein-therapeutics-research-named-suny-distinguished-professor 2026-06-23T14:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/front-line-chemo-immunotherapy-shows-promise-for-advanced-penile-cancer-in-landmark-phase-2-trial 2026-06-23T14:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/front-line-chemo-immunotherapy-shows-promise-for-advanced-penile-cancer-in-landmark-phase-2-trial 2026-06-23T14:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-secures-mhra-approval-of-pediatric-investigation-plan-for-ebstrocel-in-rdeb-clearing-key-regulatory-hurdle 2026-06-23T14:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-secures-mhra-approval-of-pediatric-investigation-plan-for-ebstrocel-in-rdeb-clearing-key-regulatory-hurdle 2026-06-23T14:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/daniel-skovronsky-eli-lilly-s-chief-scientific-officer-appointed-to-illumina-s-board-of-directors 2026-06-23T14:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daniel-skovronsky-eli-lilly-s-chief-scientific-officer-appointed-to-illumina-s-board-of-directors 2026-06-23T14:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-the-right-answer-why-medical-ai-agents-need-process-aware-benchmarks 2026-06-23T14:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-the-right-answer-why-medical-ai-agents-need-process-aware-benchmarks 2026-06-23T14:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-tighter-prior-authorization-timeframes-for-drugs-but-experts-say-fragmentation-and-transparency-gaps-remain 2026-06-23T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-tighter-prior-authorization-timeframes-for-drugs-but-experts-say-fragmentation-and-transparency-gaps-remain 2026-06-23T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/draeger-receives-fda-510-k-clearance-for-evita-v800-software-3-10-with-advanced-ards-ventilation-features 2026-06-23T13:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/draeger-receives-fda-510-k-clearance-for-evita-v800-software-3-10-with-advanced-ards-ventilation-features 2026-06-23T13:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-appoints-samuele-butera-as-svp-general-manager-global-respiratory-to-lead-brinsupri-launch-and-pipeline-expansion 2026-06-23T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-appoints-samuele-butera-as-svp-general-manager-global-respiratory-to-lead-brinsupri-launch-and-pipeline-expansion 2026-06-23T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/trimtech-therapeutics-secures-14m-extension-bringing-total-seed-round-to-47m-for-targeted-protein-degradation-in-neurodegenerative-disease 2026-06-23T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trimtech-therapeutics-secures-14m-extension-bringing-total-seed-round-to-47m-for-targeted-protein-degradation-in-neurodegenerative-disease 2026-06-23T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/women-s-clinical-trials-cros-market-to-more-than-double-by-2036-reaching-22-3-billion 2026-06-23T12:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/women-s-clinical-trials-cros-market-to-more-than-double-by-2036-reaching-22-3-billion 2026-06-23T12:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-free-ctdna-detects-molecular-residual-disease-months-before-tnbc-recurrence 2026-06-23T12:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissue-free-ctdna-detects-molecular-residual-disease-months-before-tnbc-recurrence 2026-06-23T12:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-health-clinics-expand-access-to-screenings-and-preventive-care-as-budget-pressures-mount 2026-06-23T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-health-clinics-expand-access-to-screenings-and-preventive-care-as-budget-pressures-mount 2026-06-23T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2026-un-high-level-meeting-on-hiv-aids-adopts-bold-political-declaration-reaffirming-2030-goal-to-end-aids-as-a-public-health-threat 2026-06-23T11:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-un-high-level-meeting-on-hiv-aids-adopts-bold-political-declaration-reaffirming-2030-goal-to-end-aids-as-a-public-health-threat 2026-06-23T11:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-s-department-of-health-and-sanofi-partner-to-establish-ai-enabled-vaccine-innovation-centre 2026-06-23T10:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-s-department-of-health-and-sanofi-partner-to-establish-ai-enabled-vaccine-innovation-centre 2026-06-23T10:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/inventus-control-a-purpose-built-mobile-device-management-platform-for-clinical-trials 2026-06-23T10:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventus-control-a-purpose-built-mobile-device-management-platform-for-clinical-trials 2026-06-23T10:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/florida-issues-emergency-schedule-i-ban-on-ultra-potent-7-oh-kratom-extracts-linked-to-hundreds-of-overdose-deaths 2026-06-23T09:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-issues-emergency-schedule-i-ban-on-ultra-potent-7-oh-kratom-extracts-linked-to-hundreds-of-overdose-deaths 2026-06-23T09:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-and-machine-learning-poised-to-advance-precision-medicine-in-ulcerative-colitis 2026-06-23T07:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-omics-and-machine-learning-poised-to-advance-precision-medicine-in-ulcerative-colitis 2026-06-23T07:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/pro-neuropeptide-y-emerges-as-a-circulating-biomarker-for-poor-prognosis-in-prostate-cancer 2026-06-23T07:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pro-neuropeptide-y-emerges-as-a-circulating-biomarker-for-poor-prognosis-in-prostate-cancer 2026-06-23T07:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/usf-health-recruits-internationally-renowned-physician-scientist-shyam-kottilil-to-lead-clinical-research-expansion 2026-06-23T05:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usf-health-recruits-internationally-renowned-physician-scientist-shyam-kottilil-to-lead-clinical-research-expansion 2026-06-23T05:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/wef-names-personalized-mrna-cancer-vaccines-and-exosome-drug-delivery-among-top-10-emerging-technologies-of-2026 2026-06-23T05:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wef-names-personalized-mrna-cancer-vaccines-and-exosome-drug-delivery-among-top-10-emerging-technologies-of-2026 2026-06-23T05:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-calprotectin-shows-predictive-value-for-gi-gvhd-after-allogeneic-stem-cell-transplant 2026-06-23T03:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-calprotectin-shows-predictive-value-for-gi-gvhd-after-allogeneic-stem-cell-transplant 2026-06-23T03:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/ah-008-achieves-dual-regulatory-milestones-with-u-s-fda-ind-clearance-and-taiwan-cde-index-case-designation-for-cipn-prevention 2026-06-23T03:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ah-008-achieves-dual-regulatory-milestones-with-u-s-fda-ind-clearance-and-taiwan-cde-index-case-designation-for-cipn-prevention 2026-06-23T03:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/california-and-vermont-lead-nationwide-push-to-ban-paraquat-a-pesticide-linked-to-parkinson-s-disease 2026-06-23T02:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-and-vermont-lead-nationwide-push-to-ban-paraquat-a-pesticide-linked-to-parkinson-s-disease 2026-06-23T02:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/syntax-bio-and-applied-stemcell-forge-strategic-collaboration-to-advance-crispr-based-programmable-stem-cell-therapies 2026-06-23T02:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntax-bio-and-applied-stemcell-forge-strategic-collaboration-to-advance-crispr-based-programmable-stem-cell-therapies 2026-06-23T02:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-fallon-win-cannes-lions-pharma-grand-prix-for-prostate-cancer-screening-campaign 2026-06-23T01:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-and-fallon-win-cannes-lions-pharma-grand-prix-for-prostate-cancer-screening-campaign 2026-06-23T01:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/canada-invests-892122-in-ai-driven-antimicrobial-peptide-research-to-combat-antibiotic-resistance-in-poultry 2026-06-23T01:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-invests-892122-in-ai-driven-antimicrobial-peptide-research-to-combat-antibiotic-resistance-in-poultry 2026-06-23T01:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/summer-immersion-program-equips-150-scientists-with-human-based-research-methods-wins-nih-recognition 2026-06-23T00:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summer-immersion-program-equips-150-scientists-with-human-based-research-methods-wins-nih-recognition 2026-06-23T00:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-emerges-as-stronger-2026-pick-amid-pharma-services-restructuring 2026-06-23T00:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-emerges-as-stronger-2026-pick-amid-pharma-services-restructuring 2026-06-23T00:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/who-declares-bundibugyo-virus-outbreak-a-public-health-emergency-adds-first-diagnostic-test-to-eul 2026-06-23T00:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-declares-bundibugyo-virus-outbreak-a-public-health-emergency-adds-first-diagnostic-test-to-eul 2026-06-23T00:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-launches-multi-agency-initiative-to-reclaim-u-s-leadership-in-clinical-research 2026-06-22T22:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-launches-multi-agency-initiative-to-reclaim-u-s-leadership-in-clinical-research 2026-06-22T22:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/industry-and-patient-groups-seek-changes-to-fda-s-revised-master-protocols-guidance 2026-06-22T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/industry-and-patient-groups-seek-changes-to-fda-s-revised-master-protocols-guidance 2026-06-22T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-tools-aim-to-transform-chronic-pain-management-for-rural-older-adults 2026-06-22T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-tools-aim-to-transform-chronic-pain-management-for-rural-older-adults 2026-06-22T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/utah-launches-first-ai-powered-prescription-refill-program-sparking-national-debate-on-medical-ai-regulation 2026-06-22T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utah-launches-first-ai-powered-prescription-refill-program-sparking-national-debate-on-medical-ai-regulation 2026-06-22T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-molecule-erucamide-slows-retinal-degeneration-by-activating-myeloid-immune-cells-via-tmem19 2026-06-22T20:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipid-molecule-erucamide-slows-retinal-degeneration-by-activating-myeloid-immune-cells-via-tmem19 2026-06-22T20:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/frontiers-launches-research-topic-on-cellular-dysregulation-in-autoimmune-and-autoinflammatory-diseases-seeking-novel-therapeutic-strategies 2026-06-22T20:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontiers-launches-research-topic-on-cellular-dysregulation-in-autoimmune-and-autoinflammatory-diseases-seeking-novel-therapeutic-strategies 2026-06-22T20:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/prp-injections-outperform-corticosteroids-and-nsaids-in-advanced-knee-osteoarthritis 2026-06-22T19:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prp-injections-outperform-corticosteroids-and-nsaids-in-advanced-knee-osteoarthritis 2026-06-22T19:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/caltech-researchers-borrow-bird-derived-r2-retrotransposon-to-engineer-plant-genomes-with-unprecedented-precision 2026-06-22T19:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caltech-researchers-borrow-bird-derived-r2-retrotransposon-to-engineer-plant-genomes-with-unprecedented-precision 2026-06-22T19:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/how-menopause-radically-reshapes-the-brain-energy-crisis-structural-changes-and-implications-for-alzheimer-s-risk 2026-06-22T19:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-menopause-radically-reshapes-the-brain-energy-crisis-structural-changes-and-implications-for-alzheimer-s-risk 2026-06-22T19:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-car-t-cells-offer-one-shot-remission-in-rheumatoid-arthritis-preclinical-study-shows 2026-06-22T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-car-t-cells-offer-one-shot-remission-in-rheumatoid-arthritis-preclinical-study-shows 2026-06-22T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-s-dr-theodore-scott-nowicki-receives-100000-hero-grant-to-advance-armed-car-t-therapy-for-pediatric-osteosarcoma 2026-06-22T19:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-s-dr-theodore-scott-nowicki-receives-100000-hero-grant-to-advance-armed-car-t-therapy-for-pediatric-osteosarcoma 2026-06-22T19:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/copper-induced-cell-death-activates-immune-system-offering-new-strategy-to-overcome-immunotherapy-resistance 2026-06-22T19:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/copper-induced-cell-death-activates-immune-system-offering-new-strategy-to-overcome-immunotherapy-resistance 2026-06-22T19:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/keio-university-launches-11th-healthcare-venture-contest-with-focus-on-mibyou-pre-symptomatic-measures-and-entrepreneurial-strategy 2026-06-22T19:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keio-university-launches-11th-healthcare-venture-contest-with-focus-on-mibyou-pre-symptomatic-measures-and-entrepreneurial-strategy 2026-06-22T19:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/study-identifies-birthweight-sex-ethnicity-and-paternal-age-as-risk-factors-for-early-onset-colorectal-cancer 2026-06-22T17:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-identifies-birthweight-sex-ethnicity-and-paternal-age-as-risk-factors-for-early-onset-colorectal-cancer 2026-06-22T17:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-health-experts-cut-through-the-hype-fiber-fermented-foods-and-food-safety-caution-outrank-probiotic-pills 2026-06-22T17:23:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-health-experts-cut-through-the-hype-fiber-fermented-foods-and-food-safety-caution-outrank-probiotic-pills 2026-06-22T17:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/walmart-and-sam-s-club-launch-nationwide-medicare-navigation-initiative-as-glp-1-bridge-program-takes-effect 2026-06-22T17:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walmart-and-sam-s-club-launch-nationwide-medicare-navigation-initiative-as-glp-1-bridge-program-takes-effect 2026-06-22T17:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/oatmeal-avocado-and-peppermint-oil-emerging-evidence-for-dietary-adjuncts-in-type-2-diabetes-management 2026-06-22T17:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oatmeal-avocado-and-peppermint-oil-emerging-evidence-for-dietary-adjuncts-in-type-2-diabetes-management 2026-06-22T17:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/promising-single-dose-malaria-therapy-spap-advances-toward-pan-african-clinical-trial 2026-06-22T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-single-dose-malaria-therapy-spap-advances-toward-pan-african-clinical-trial 2026-06-22T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/growth-hormone-therapy-in-children-unanswered-questions-on-musculoskeletal-safety-long-term-outcomes-and-precision-monitoring 2026-06-22T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/growth-hormone-therapy-in-children-unanswered-questions-on-musculoskeletal-safety-long-term-outcomes-and-precision-monitoring 2026-06-22T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/california-s-life-science-industry-faces-policy-crossroads-as-economic-impact-hits-394-billion 2026-06-22T17:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-s-life-science-industry-faces-policy-crossroads-as-economic-impact-hits-394-billion 2026-06-22T17:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/massive-open-access-chemistry-database-powers-ai-driven-drug-discovery-and-catalyst-innovation 2026-06-22T17:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-open-access-chemistry-database-powers-ai-driven-drug-discovery-and-catalyst-innovation 2026-06-22T17:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/betterlife-pharma-appoints-mahan-chehrenama-do-as-chief-medical-officer-to-lead-betr-001-toward-migraine-ind 2026-06-22T17:20:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/betterlife-pharma-appoints-mahan-chehrenama-do-as-chief-medical-officer-to-lead-betr-001-toward-migraine-ind 2026-06-22T17:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/uwf-researcher-secures-825000-florida-cancer-innovation-grant-to-launch-statewide-lifestyle-intervention-for-breast-and-prostate-cancer-survivors 2026-06-22T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uwf-researcher-secures-825000-florida-cancer-innovation-grant-to-launch-statewide-lifestyle-intervention-for-breast-and-prostate-cancer-survivors 2026-06-22T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/international-patents-granted-for-remedee-labs-endorphin-stimulating-mmwave-wristband-for-chronic-pain 2026-06-22T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-patents-granted-for-remedee-labs-endorphin-stimulating-mmwave-wristband-for-chronic-pain 2026-06-22T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/new-p-tefb-bhlhe40-tim8-tim13-axis-reveals-hif-independent-hypoxic-gene-regulation-in-treatment-resistant-tumors 2026-06-22T16:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-p-tefb-bhlhe40-tim8-tim13-axis-reveals-hif-independent-hypoxic-gene-regulation-in-treatment-resistant-tumors 2026-06-22T16:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-to-acquire-memo-therapeutics-in-deal-worth-over-eur700-million-securing-phase-ii-bk-polyomavirus-antibody-potravitug 2026-06-22T16:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-to-acquire-memo-therapeutics-in-deal-worth-over-eur700-million-securing-phase-ii-bk-polyomavirus-antibody-potravitug 2026-06-22T16:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-declines-to-approve-achieve-life-sciences-cytisinicline-for-smoking-cessation-citing-manufacturing-issues-only 2026-06-22T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-declines-to-approve-achieve-life-sciences-cytisinicline-for-smoking-cessation-citing-manufacturing-issues-only 2026-06-22T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/dea-kicks-off-historic-cannabis-rescheduling-hearing-amid-lawsuits-and-exclusion-controversy 2026-06-22T16:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-kicks-off-historic-cannabis-rescheduling-hearing-amid-lawsuits-and-exclusion-controversy 2026-06-22T16:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/china-closing-in-but-us-still-leads-in-biotech-innovation-cure-survey-finds 2026-06-22T16:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-closing-in-but-us-still-leads-in-biotech-innovation-cure-survey-finds 2026-06-22T16:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/paul-weiss-and-kirkland-steer-abbvie-s-10-9-billion-acquisition-of-apogee-therapeutics 2026-06-22T16:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paul-weiss-and-kirkland-steer-abbvie-s-10-9-billion-acquisition-of-apogee-therapeutics 2026-06-22T16:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/nih-sennet-consortium-unveils-first-comprehensive-atlas-of-senescent-cells-introducing-senotypes-framework 2026-06-22T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-sennet-consortium-unveils-first-comprehensive-atlas-of-senescent-cells-introducing-senotypes-framework 2026-06-22T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/systemic-immunotherapy-transforms-advanced-cutaneous-squamous-cell-carcinoma-management-mechanistic-insights-guide-agent-selection 2026-06-22T15:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systemic-immunotherapy-transforms-advanced-cutaneous-squamous-cell-carcinoma-management-mechanistic-insights-guide-agent-selection 2026-06-22T15:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/leerink-partners-strengthens-oncology-research-with-veteran-biotech-analyst-asthika-goonewardene 2026-06-22T15:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leerink-partners-strengthens-oncology-research-with-veteran-biotech-analyst-asthika-goonewardene 2026-06-22T15:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/orano-med-leverages-nuclear-fuel-legacy-to-chase-radiopharma-leadership-with-lead-212-therapies 2026-06-22T15:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orano-med-leverages-nuclear-fuel-legacy-to-chase-radiopharma-leadership-with-lead-212-therapies 2026-06-22T15:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/dropgenie-secures-seed-financing-to-launch-miniaturized-gene-editing-platform-for-primary-cell-applications 2026-06-22T15:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dropgenie-secures-seed-financing-to-launch-miniaturized-gene-editing-platform-for-primary-cell-applications 2026-06-22T15:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/polymyxin-b-mic-1-mg-l-predicts-reduced-clinical-cure-and-pk-pd-target-attainment-in-carbapenem-resistant-enterobacterales-infections 2026-06-22T14:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polymyxin-b-mic-1-mg-l-predicts-reduced-clinical-cure-and-pk-pd-target-attainment-in-carbapenem-resistant-enterobacterales-infections 2026-06-22T14:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-analytics-and-ai-are-reshaping-medication-adherence-moving-beyond-patient-education-to-actionable-intervention 2026-06-22T14:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-analytics-and-ai-are-reshaping-medication-adherence-moving-beyond-patient-education-to-actionable-intervention 2026-06-22T14:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-doses-first-u-s-and-japanese-patients-in-phase-3-cove-3-trial-of-ycanth-for-common-warts 2026-06-22T14:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-doses-first-u-s-and-japanese-patients-in-phase-3-cove-3-trial-of-ycanth-for-common-warts 2026-06-22T14:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-launches-biotech-incubator-with-cape-fear-biocapital-to-bridge-early-stage-innovation-and-clinical-development-expertise 2026-06-22T14:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parexel-launches-biotech-incubator-with-cape-fear-biocapital-to-bridge-early-stage-innovation-and-clinical-development-expertise 2026-06-22T14:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-presents-exploratory-biomarker-data-at-aaic-2026-linking-spectris-neuromodulation-to-lipid-transport-and-myelination-pathways-in-alzheimer-s-disease 2026-06-22T14:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognito-therapeutics-presents-exploratory-biomarker-data-at-aaic-2026-linking-spectris-neuromodulation-to-lipid-transport-and-myelination-pathways-in-alzheimer-s-disease 2026-06-22T14:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-in-the-world-treated-with-gene-therapy-for-cockayne-syndrome 2026-06-22T14:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-in-the-world-treated-with-gene-therapy-for-cockayne-syndrome 2026-06-22T14:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/aptorum-group-and-diamir-biosciences-advance-merger-launch-alzheimer-s-biomarker-collaboration-with-alzlabs 2026-06-22T14:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptorum-group-and-diamir-biosciences-advance-merger-launch-alzheimer-s-biomarker-collaboration-with-alzlabs 2026-06-22T14:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-dna-repair-therapies-open-new-frontiers-in-oncology 2026-06-22T14:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-dna-repair-therapies-open-new-frontiers-in-oncology 2026-06-22T14:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-silevimig-the-world-s-first-bispecific-antibody-for-rabies-passive-immunization 2026-06-22T14:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-silevimig-the-world-s-first-bispecific-antibody-for-rabies-passive-immunization 2026-06-22T14:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-biomarker-p-tau217-may-identify-women-at-higher-dementia-risk-from-combined-hormone-therapy 2026-06-22T14:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-biomarker-p-tau217-may-identify-women-at-higher-dementia-risk-from-combined-hormone-therapy 2026-06-22T14:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/ellison-medical-institute-and-uniquest-partner-to-advance-first-in-class-trpv6-targeting-therapy-for-resistant-prostate-cancer 2026-06-22T14:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ellison-medical-institute-and-uniquest-partner-to-advance-first-in-class-trpv6-targeting-therapy-for-resistant-prostate-cancer 2026-06-22T14:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/first-ascent-biomedical-appoints-raymond-rodriguez-torres-as-president-to-scale-functional-precision-oncology-platform 2026-06-22T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ascent-biomedical-appoints-raymond-rodriguez-torres-as-president-to-scale-functional-precision-oncology-platform 2026-06-22T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/drug-response-profiling-with-ai-identifies-optimal-drug-combinations-for-children-with-relapsed-all 2026-06-22T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-response-profiling-with-ai-identifies-optimal-drug-combinations-for-children-with-relapsed-all 2026-06-22T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-s-pm359-gains-fda-rmat-designation-for-p47phox-deficient-chronic-granulomatous-disease 2026-06-22T13:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-s-pm359-gains-fda-rmat-designation-for-p47phox-deficient-chronic-granulomatous-disease 2026-06-22T13:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/nuvectis-in-licenses-two-clinical-stage-assets-from-haisco-transforming-into-late-stage-biopharma-with-oral-factor-b-and-paradox-breaker-braf-inhibitors 2026-06-22T12:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvectis-in-licenses-two-clinical-stage-assets-from-haisco-transforming-into-late-stage-biopharma-with-oral-factor-b-and-paradox-breaker-braf-inhibitors 2026-06-22T12:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/graph-therapeutics-secures-5m-to-advance-ai-powered-precision-immunology-pipeline 2026-06-22T12:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graph-therapeutics-secures-5m-to-advance-ai-powered-precision-immunology-pipeline 2026-06-22T12:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-tetmedical-s-nse-fast-the-first-rapid-blood-test-for-acute-ischemic-stroke-diagnosis 2026-06-22T12:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-tetmedical-s-nse-fast-the-first-rapid-blood-test-for-acute-ischemic-stroke-diagnosis 2026-06-22T12:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/biond-biologics-appoints-veteran-immuno-oncology-executive-giovanni-selvaggi-as-chief-medical-officer 2026-06-22T12:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biond-biologics-appoints-veteran-immuno-oncology-executive-giovanni-selvaggi-as-chief-medical-officer 2026-06-22T12:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/wits-professor-yahya-choonara-elected-to-controlled-release-society-college-of-fellows-marking-global-recognition-for-african-drug-delivery-research 2026-06-22T12:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wits-professor-yahya-choonara-elected-to-controlled-release-society-college-of-fellows-marking-global-recognition-for-african-drug-delivery-research 2026-06-22T12:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/vaccine-confidence-waning-protection-and-the-next-generation-of-respiratory-disease-prevention-insights-from-leading-clinicians 2026-06-22T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccine-confidence-waning-protection-and-the-next-generation-of-respiratory-disease-prevention-insights-from-leading-clinicians 2026-06-22T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/curewise-launches-ai-powered-precision-oncology-platform-at-aspen-ideas-health-2026 2026-06-22T12:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curewise-launches-ai-powered-precision-oncology-platform-at-aspen-ideas-health-2026 2026-06-22T12:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-tulisokibart-becomes-first-anti-tl1a-biologic-to-achieve-phase-3-clinical-remission-in-ulcerative-colitis 2026-06-22T12:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-tulisokibart-becomes-first-anti-tl1a-biologic-to-achieve-phase-3-clinical-remission-in-ulcerative-colitis 2026-06-22T12:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-clinical-trial-registrations-surpass-5000-for-first-time-in-2025-doubling-2020-figures 2026-06-22T12:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-clinical-trial-registrations-surpass-5000-for-first-time-in-2025-doubling-2020-figures 2026-06-22T12:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/bangladeshi-firm-beximco-launches-generic-trikafta-at-96-discount-exploiting-wto-patent-waiver-for-cystic-fibrosis-patients 2026-06-22T12:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladeshi-firm-beximco-launches-generic-trikafta-at-96-discount-exploiting-wto-patent-waiver-for-cystic-fibrosis-patients 2026-06-22T12:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/ctt-pharma-secures-u-s-patent-for-micelle-based-nicotine-vitamin-and-caffeine-oral-delivery-platform 2026-06-22T12:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctt-pharma-secures-u-s-patent-for-micelle-based-nicotine-vitamin-and-caffeine-oral-delivery-platform 2026-06-22T12:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/tavr-rewrites-structural-heart-care-as-heart-valve-devices-market-projects-11-2-cagr-through-2032 2026-06-22T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tavr-rewrites-structural-heart-care-as-heart-valve-devices-market-projects-11-2-cagr-through-2032 2026-06-22T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/baylor-college-of-medicine-s-k-12-health-science-model-builds-the-future-health-care-workforce 2026-06-22T12:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baylor-college-of-medicine-s-k-12-health-science-model-builds-the-future-health-care-workforce 2026-06-22T12:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/enamine-marks-35-years-as-a-global-drug-discovery-partner-powered-by-the-real-chemical-space 2026-06-22T12:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enamine-marks-35-years-as-a-global-drug-discovery-partner-powered-by-the-real-chemical-space 2026-06-22T12:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/karmanos-cancer-institute-reports-historic-47-growth-in-new-cancer-cases-cementing-leadership-in-oncology-care-delivery 2026-06-22T11:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karmanos-cancer-institute-reports-historic-47-growth-in-new-cancer-cases-cementing-leadership-in-oncology-care-delivery 2026-06-22T11:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/unexplained-skin-darkening-leads-to-life-saving-addison-s-disease-diagnosis-in-24-year-old-woman 2026-06-22T11:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unexplained-skin-darkening-leads-to-life-saving-addison-s-disease-diagnosis-in-24-year-old-woman 2026-06-22T11:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/the-first-14-days-how-specialty-pharmacy-programs-drive-treatment-initiation-and-adherence 2026-06-22T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-first-14-days-how-specialty-pharmacy-programs-drive-treatment-initiation-and-adherence 2026-06-22T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/dyadic-s-c1-platform-gains-momentum-as-ebola-outbreak-highlights-urgent-need-for-rapid-biologics-manufacturing 2026-06-22T11:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyadic-s-c1-platform-gains-momentum-as-ebola-outbreak-highlights-urgent-need-for-rapid-biologics-manufacturing 2026-06-22T11:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/sareum-completes-dosing-in-phase-2-enabling-toxicology-programme-for-tyk2-jak1-inhibitor-sdc-1801 2026-06-22T11:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sareum-completes-dosing-in-phase-2-enabling-toxicology-programme-for-tyk2-jak1-inhibitor-sdc-1801 2026-06-22T11:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/algae-based-microrobots-boost-bladder-cancer-drug-penetration-tenfold-in-preclinical-study 2026-06-22T11:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algae-based-microrobots-boost-bladder-cancer-drug-penetration-tenfold-in-preclinical-study 2026-06-22T11:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/chemdiv-cns-platform-drives-neurodegenerative-programs-into-clinic-for-brenig-and-polku-therapeutics 2026-06-22T11:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemdiv-cns-platform-drives-neurodegenerative-programs-into-clinic-for-brenig-and-polku-therapeutics 2026-06-22T11:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/pheno-therapeutics-gains-fda-ind-clearance-for-first-in-class-gpr17-antagonist-ptd802-in-multiple-sclerosis 2026-06-22T10:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pheno-therapeutics-gains-fda-ind-clearance-for-first-in-class-gpr17-antagonist-ptd802-in-multiple-sclerosis 2026-06-22T10:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-int230-6-turning-solid-tumors-into-personalized-anti-cancer-vaccines 2026-06-22T08:49:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-int230-6-turning-solid-tumors-into-personalized-anti-cancer-vaccines 2026-06-22T08:49:55+00:00 hourly 0.9 https://trial.medpath.com/news/circular-rna-emerges-as-next-generation-therapeutic-platform-with-big-pharma-backing 2026-06-22T08:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-rna-emerges-as-next-generation-therapeutic-platform-with-big-pharma-backing 2026-06-22T08:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/south-africa-s-indigenous-cancer-bush-shows-promise-against-drug-resistant-cancers-in-preclinical-studies 2026-06-22T08:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-africa-s-indigenous-cancer-bush-shows-promise-against-drug-resistant-cancers-in-preclinical-studies 2026-06-22T08:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/gabbard-releases-declassified-documents-alleging-fauci-orchestrated-covid-19-origins-cover-up 2026-06-22T08:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gabbard-releases-declassified-documents-alleging-fauci-orchestrated-covid-19-origins-cover-up 2026-06-22T08:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/bioarctic-and-lilly-ink-800-million-neurodegeneration-deal-leveraging-braintransporter-technology 2026-06-22T08:47:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioarctic-and-lilly-ink-800-million-neurodegeneration-deal-leveraging-braintransporter-technology 2026-06-22T08:47:18+00:00 hourly 0.9 https://trial.medpath.com/news/when-the-sponsor-s-it-goes-down-the-trial-goes-with-it-cyberattack-exposure-in-clinical-trial-delivery 2026-06-22T08:46:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/when-the-sponsor-s-it-goes-down-the-trial-goes-with-it-cyberattack-exposure-in-clinical-trial-delivery 2026-06-22T08:46:56+00:00 hourly 0.9 https://trial.medpath.com/news/milford-wellness-village-anchors-1-25m-federal-grant-for-chronic-disease-self-management-program 2026-06-22T08:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milford-wellness-village-anchors-1-25m-federal-grant-for-chronic-disease-self-management-program 2026-06-22T08:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-appoints-paulo-fontoura-as-global-head-of-r-d-succeeding-houman-ashrafian 2026-06-22T07:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-appoints-paulo-fontoura-as-global-head-of-r-d-succeeding-houman-ashrafian 2026-06-22T07:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/autonomous-medical-ai-agent-mira-outperforms-physicians-in-simulated-ehr-diagnostic-cases 2026-06-22T06:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomous-medical-ai-agent-mira-outperforms-physicians-in-simulated-ehr-diagnostic-cases 2026-06-22T06:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/ebola-and-hantavirus-what-clinicians-need-to-know-about-these-deadly-infectious-diseases 2026-06-22T05:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebola-and-hantavirus-what-clinicians-need-to-know-about-these-deadly-infectious-diseases 2026-06-22T05:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/vietnamese-scientists-develop-nanovitexin-from-mung-bean-husks-to-enhance-diabetes-treatment 2026-06-22T04:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnamese-scientists-develop-nanovitexin-from-mung-bean-husks-to-enhance-diabetes-treatment 2026-06-22T04:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-data-reveals-immediate-impact-of-medical-training-prioritisation-act-uk-trained-doctors-fill-98-of-specialty-posts 2026-06-22T04:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-data-reveals-immediate-impact-of-medical-training-prioritisation-act-uk-trained-doctors-fill-98-of-specialty-posts 2026-06-22T04:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/functional-foods-and-bioactive-compounds-emerge-as-multi-target-strategy-for-metabolic-syndrome 2026-06-22T04:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/functional-foods-and-bioactive-compounds-emerge-as-multi-target-strategy-for-metabolic-syndrome 2026-06-22T04:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/catvariant-new-open-access-platform-from-uc-davis-streamlines-genetic-variant-interpretation 2026-06-22T03:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catvariant-new-open-access-platform-from-uc-davis-streamlines-genetic-variant-interpretation 2026-06-22T03:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/nab-paclitaxel-plus-s-1-shows-promise-as-induction-therapy-for-locally-advanced-pancreatic-cancer 2026-06-22T02:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nab-paclitaxel-plus-s-1-shows-promise-as-induction-therapy-for-locally-advanced-pancreatic-cancer 2026-06-22T02:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/protinah-signs-ppi-biomarker-analysis-agreement-with-u-s-multinational-pharma-for-neurodegenerative-drug-development 2026-06-22T02:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protinah-signs-ppi-biomarker-analysis-agreement-with-u-s-multinational-pharma-for-neurodegenerative-drug-development 2026-06-22T02:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/prg-s-tech-s-trineumin-receives-therapeutic-use-approval-in-korea-for-nf2-the-world-s-first-small-molecule-targeting-the-disease-mechanism 2026-06-22T02:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prg-s-tech-s-trineumin-receives-therapeutic-use-approval-in-korea-for-nf2-the-world-s-first-small-molecule-targeting-the-disease-mechanism 2026-06-22T02:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/rethinking-patient-and-public-involvement-why-process-matters-as-much-as-impact-in-preclinical-research 2026-06-22T02:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rethinking-patient-and-public-involvement-why-process-matters-as-much-as-impact-in-preclinical-research 2026-06-22T02:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/host-microbiome-immune-disequilibrium-a-new-framework-for-understanding-and-treating-oral-diseases 2026-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/host-microbiome-immune-disequilibrium-a-new-framework-for-understanding-and-treating-oral-diseases 2026-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiota-brain-axis-emerges-as-key-regulator-of-post-stroke-cognitive-impairment-through-epigenetic-mechanisms 2026-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiota-brain-axis-emerges-as-key-regulator-of-post-stroke-cognitive-impairment-through-epigenetic-mechanisms 2026-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/generative-ai-is-reshaping-scientific-ideation-but-experience-determines-who-benefits 2026-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generative-ai-is-reshaping-scientific-ideation-but-experience-determines-who-benefits 2026-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/microplastics-accumulate-in-human-brains-at-alarming-levels-new-research-shows 2026-06-21T23:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microplastics-accumulate-in-human-brains-at-alarming-levels-new-research-shows 2026-06-21T23:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/super-potent-synthetic-opioids-called-nitazenes-are-spreading-across-the-u-s-with-ohio-bearing-the-brunt 2026-06-21T23:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/super-potent-synthetic-opioids-called-nitazenes-are-spreading-across-the-u-s-with-ohio-bearing-the-brunt 2026-06-21T23:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/understanding-atopic-dermatitis-barrier-breakdown-the-itch-scratch-cycle-and-the-rational-use-of-topical-steroids 2026-06-21T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/understanding-atopic-dermatitis-barrier-breakdown-the-itch-scratch-cycle-and-the-rational-use-of-topical-steroids 2026-06-21T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/duke-researchers-discover-gpcrs-signal-through-liquid-like-protein-condensates-opening-new-avenues-for-drug-development 2026-06-21T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-researchers-discover-gpcrs-signal-through-liquid-like-protein-condensates-opening-new-avenues-for-drug-development 2026-06-21T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/maricopa-county-reports-sharp-increase-in-west-nile-virus-cases-and-first-deaths-of-2026 2026-06-21T22:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maricopa-county-reports-sharp-increase-in-west-nile-virus-cases-and-first-deaths-of-2026 2026-06-21T22:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-australian-study-shows-digital-nutrition-program-can-reverse-type-2-diabetes-in-nearly-one-in-five-participants 2026-06-21T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-australian-study-shows-digital-nutrition-program-can-reverse-type-2-diabetes-in-nearly-one-in-five-participants 2026-06-21T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/ai-derived-biomarker-from-routine-pathology-images-predicts-individual-benefit-from-parp-inhibitors-in-ovarian-cancer 2026-06-21T19:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-derived-biomarker-from-routine-pathology-images-predicts-individual-benefit-from-parp-inhibitors-in-ovarian-cancer 2026-06-21T19:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-suspends-hcg-central-ethics-committee-for-24-months-over-serious-clinical-trial-safety-violations 2026-06-21T19:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-suspends-hcg-central-ethics-committee-for-24-months-over-serious-clinical-trial-safety-violations 2026-06-21T19:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-metabolites-emerge-as-key-modulators-of-immune-checkpoint-inhibitor-efficacy-and-toxicity 2026-06-21T18:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-metabolites-emerge-as-key-modulators-of-immune-checkpoint-inhibitor-efficacy-and-toxicity 2026-06-21T18:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/rethinking-the-menopause-hormone-therapy-question-why-can-i-take-hrt-is-the-wrong-starting-point 2026-06-21T18:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rethinking-the-menopause-hormone-therapy-question-why-can-i-take-hrt-is-the-wrong-starting-point 2026-06-21T18:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/nanobody-based-bispecific-antibody-delivers-broad-spectrum-protection-against-multiple-ebolavirus-species 2026-06-21T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobody-based-bispecific-antibody-delivers-broad-spectrum-protection-against-multiple-ebolavirus-species 2026-06-21T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/long-lived-families-reveal-rare-cgas-gene-variant-linked-to-extended-healthspan 2026-06-21T17:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-lived-families-reveal-rare-cgas-gene-variant-linked-to-extended-healthspan 2026-06-21T17:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-footage-captures-macrophages-engulfing-live-melanoma-cells-revealing-new-therapeutic-avenue 2026-06-21T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-footage-captures-macrophages-engulfing-live-melanoma-cells-revealing-new-therapeutic-avenue 2026-06-21T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-unveil-highest-resolution-human-proteome-map-opening-new-frontiers-in-drug-discovery-and-precision-oncology 2026-06-21T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-unveil-highest-resolution-human-proteome-map-opening-new-frontiers-in-drug-discovery-and-precision-oncology 2026-06-21T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/human-ai-teaming-improves-oncology-clinical-trial-prescreening-accuracy-without-slowing-workflow 2026-06-21T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-ai-teaming-improves-oncology-clinical-trial-prescreening-accuracy-without-slowing-workflow 2026-06-21T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/heatwave-warning-beta-blockers-metformin-and-ssris-pose-dehydration-and-heat-related-risks-uk-regulators-and-physicians-caution 2026-06-21T16:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heatwave-warning-beta-blockers-metformin-and-ssris-pose-dehydration-and-heat-related-risks-uk-regulators-and-physicians-caution 2026-06-21T16:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/inside-russia-s-26-billion-state-backed-longevity-program-bioprinting-gene-therapy-and-the-politics-of-anti-aging-research 2026-06-21T16:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inside-russia-s-26-billion-state-backed-longevity-program-bioprinting-gene-therapy-and-the-politics-of-anti-aging-research 2026-06-21T16:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/daily-multivitamin-shows-modest-functional-health-benefits-in-older-adults-cosmos-trial-secondary-analysis 2026-06-21T15:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-multivitamin-shows-modest-functional-health-benefits-in-older-adults-cosmos-trial-secondary-analysis 2026-06-21T15:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-review-concludes-vaping-likely-causes-lung-and-oral-cancer-drawing-parallels-to-tobacco-history 2026-06-21T15:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-review-concludes-vaping-likely-causes-lung-and-oral-cancer-drawing-parallels-to-tobacco-history 2026-06-21T15:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/bexorg-appoints-bruce-car-as-cso-and-michael-fenn-as-cbo-strengthening-leadership-for-ai-driven-precision-neurology-platform 2026-06-21T15:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexorg-appoints-bruce-car-as-cso-and-michael-fenn-as-cbo-strengthening-leadership-for-ai-driven-precision-neurology-platform 2026-06-21T15:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/transplanted-neural-progenitor-cells-survive-one-year-in-retinitis-pigmentosa-patients-phase-1-2a-trial-shows 2026-06-21T14:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transplanted-neural-progenitor-cells-survive-one-year-in-retinitis-pigmentosa-patients-phase-1-2a-trial-shows 2026-06-21T14:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-half-of-kidney-transplant-candidates-never-begin-evaluation-landmark-study-finds 2026-06-21T13:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-half-of-kidney-transplant-candidates-never-begin-evaluation-landmark-study-finds 2026-06-21T13:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twin-of-immunity-russian-mathematical-model-aims-to-accelerate-drug-development-for-arthritis-and-diabetes 2026-06-21T13:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-twin-of-immunity-russian-mathematical-model-aims-to-accelerate-drug-development-for-arthritis-and-diabetes 2026-06-21T13:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/bellvitge-advances-toward-personalized-als-care-through-novel-biomarkers-and-digital-technologies 2026-06-21T12:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bellvitge-advances-toward-personalized-als-care-through-novel-biomarkers-and-digital-technologies 2026-06-21T12:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/australia-relaxes-psychedelic-assisted-therapy-rules-sparking-safety-debate-among-clinicians 2026-06-21T11:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-relaxes-psychedelic-assisted-therapy-rules-sparking-safety-debate-among-clinicians 2026-06-21T11:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-genomic-medicine-rapid-progress-demands-measured-integration-2026-howland-lecture-warns 2026-06-21T10:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-genomic-medicine-rapid-progress-demands-measured-integration-2026-howland-lecture-warns 2026-06-21T10:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-vaccination-linked-to-near-zero-cervical-cancer-mortality-in-young-women-landmark-uk-study-finds 2026-06-21T06:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpv-vaccination-linked-to-near-zero-cervical-cancer-mortality-in-young-women-landmark-uk-study-finds 2026-06-21T06:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biopharma-leaders-target-global-partnerships-at-bio-2026-in-san-diego 2026-06-21T05:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-biopharma-leaders-target-global-partnerships-at-bio-2026-in-san-diego 2026-06-21T05:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/former-jd-com-executive-cai-lei-wages-ai-powered-war-against-als-advancing-nearly-300-drug-pipelines 2026-06-21T05:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-jd-com-executive-cai-lei-wages-ai-powered-war-against-als-advancing-nearly-300-drug-pipelines 2026-06-21T05:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-medline-over-significant-cgmp-violations-including-microbial-contamination-failures 2026-06-21T05:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letter-to-medline-over-significant-cgmp-violations-including-microbial-contamination-failures 2026-06-21T05:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/ray-kurzweil-predicts-longevity-escape-velocity-by-2032-fueled-by-ai-driven-drug-discovery 2026-06-21T04:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ray-kurzweil-predicts-longevity-escape-velocity-by-2032-fueled-by-ai-driven-drug-discovery 2026-06-21T04:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/curegene-doses-first-participant-in-u-s-pivotal-trial-of-evategrel-a-novel-dual-formulation-p2y12-inhibitor 2026-06-21T03:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curegene-doses-first-participant-in-u-s-pivotal-trial-of-evategrel-a-novel-dual-formulation-p2y12-inhibitor 2026-06-21T03:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/shapiro-administration-expands-overdose-prevention-program-saving-over-16000-lives-through-naloxone-distribution 2026-06-21T02:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shapiro-administration-expands-overdose-prevention-program-saving-over-16000-lives-through-naloxone-distribution 2026-06-21T02:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/malaysia-moves-toward-vape-ban-after-402-cases-of-synthetic-drug-laced-e-cigarette-liquids-detected 2026-06-21T02:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysia-moves-toward-vape-ban-after-402-cases-of-synthetic-drug-laced-e-cigarette-liquids-detected 2026-06-21T02:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-relax-your-tight-end-prostate-cancer-screening-campaign-wins-pharma-grand-prix-at-cannes-lions-2026 2026-06-21T00:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-relax-your-tight-end-prostate-cancer-screening-campaign-wins-pharma-grand-prix-at-cannes-lions-2026 2026-06-21T00:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/nepal-s-drug-administration-moves-to-end-two-month-cancer-drug-shortage-with-minimum-stock-system 2026-06-21T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nepal-s-drug-administration-moves-to-end-two-month-cancer-drug-shortage-with-minimum-stock-system 2026-06-21T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-european-cancer-organisation-report-calls-for-equitable-access-to-precision-cancer-medicine-across-europe 2026-06-20T23:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-european-cancer-organisation-report-calls-for-equitable-access-to-precision-cancer-medicine-across-europe 2026-06-20T23:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/heliconius-butterflies-reveal-novel-pro-longevity-mechanisms-beyond-diet-offering-insights-into-healthy-aging 2026-06-20T22:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heliconius-butterflies-reveal-novel-pro-longevity-mechanisms-beyond-diet-offering-insights-into-healthy-aging 2026-06-20T22:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nci-highlights-blinatumomab-and-atezolizumab-advances-as-childhood-cancer-data-initiative-scales-up 2026-06-20T21:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nci-highlights-blinatumomab-and-atezolizumab-advances-as-childhood-cancer-data-initiative-scales-up 2026-06-20T21:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/nobel-laureate-john-jumper-leaves-google-deepmind-for-anthropic-signaling-ai-talent-shift-toward-life-sciences 2026-06-20T21:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nobel-laureate-john-jumper-leaves-google-deepmind-for-anthropic-signaling-ai-talent-shift-toward-life-sciences 2026-06-20T21:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/international-survey-reveals-profound-gaps-in-cardio-oncology-training-across-63-countries 2026-06-20T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-survey-reveals-profound-gaps-in-cardio-oncology-training-across-63-countries 2026-06-20T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/after-the-drug-substance-the-real-squeeze-apac-s-aseptic-fill-finish-gap 2026-06-20T20:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/after-the-drug-substance-the-real-squeeze-apac-s-aseptic-fill-finish-gap 2026-06-20T20:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/consensus-roadmap-proposes-redesign-of-clinical-trials-for-rare-childhood-cns-tumours 2026-06-20T20:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/consensus-roadmap-proposes-redesign-of-clinical-trials-for-rare-childhood-cns-tumours 2026-06-20T20:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-s-8-billion-dtc-ad-spend-fails-to-translate-into-ai-citation-share-5w-index-finds 2026-06-20T20:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-s-8-billion-dtc-ad-spend-fails-to-translate-into-ai-citation-share-5w-index-finds 2026-06-20T20:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-ever-phytochemical-and-botanical-reference-standards-to-advance-phytopharmaceutical-quality 2026-06-20T19:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-first-ever-phytochemical-and-botanical-reference-standards-to-advance-phytopharmaceutical-quality 2026-06-20T19:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/medicine-shortages-deepen-in-iran-as-sanctions-blockade-and-war-strain-the-pharmaceutical-supply-chain 2026-06-20T19:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicine-shortages-deepen-in-iran-as-sanctions-blockade-and-war-strain-the-pharmaceutical-supply-chain 2026-06-20T19:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/provectus-biopharmaceuticals-to-deliver-broad-strategic-update-at-2026-annual-stockholder-meeting 2026-06-20T19:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/provectus-biopharmaceuticals-to-deliver-broad-strategic-update-at-2026-annual-stockholder-meeting 2026-06-20T19:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/spermidine-in-alzheimer-s-disease-preclinical-promise-meets-limited-clinical-evidence 2026-06-20T18:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spermidine-in-alzheimer-s-disease-preclinical-promise-meets-limited-clinical-evidence 2026-06-20T18:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/traveling-waves-of-protein-activity-tell-the-mitotic-spindle-how-big-to-be 2026-06-20T18:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traveling-waves-of-protein-activity-tell-the-mitotic-spindle-how-big-to-be 2026-06-20T18:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/andhra-pradesh-to-establish-state-level-rare-disease-policy-by-2026-aligning-with-national-framework 2026-06-20T18:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andhra-pradesh-to-establish-state-level-rare-disease-policy-by-2026-aligning-with-national-framework 2026-06-20T18:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/drug-decriminalisation-holds-the-key-to-ending-aids-among-people-who-use-drugs-un-guidance-and-global-coalitions-argue 2026-06-20T18:05:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-decriminalisation-holds-the-key-to-ending-aids-among-people-who-use-drugs-un-guidance-and-global-coalitions-argue 2026-06-20T18:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/psychologist-warns-dna-testing-kits-can-trigger-identity-disruption-and-psychological-harm 2026-06-20T18:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychologist-warns-dna-testing-kits-can-trigger-identity-disruption-and-psychological-harm 2026-06-20T18:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/candida-auris-candidemia-sofa-score-predicts-mortality-as-echinocandins-remain-effective-first-line-therapy 2026-06-20T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candida-auris-candidemia-sofa-score-predicts-mortality-as-echinocandins-remain-effective-first-line-therapy 2026-06-20T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-terpenes-show-promise-for-fibromyalgia-and-post-surgical-pain-relief-without-psychoactive-effects 2026-06-20T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-terpenes-show-promise-for-fibromyalgia-and-post-surgical-pain-relief-without-psychoactive-effects 2026-06-20T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/helicobacter-pylori-drives-76-of-projected-15-6-million-stomach-cancers-underscoring-urgent-case-for-screening 2026-06-20T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helicobacter-pylori-drives-76-of-projected-15-6-million-stomach-cancers-underscoring-urgent-case-for-screening 2026-06-20T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/rbm41-drives-colorectal-cancer-by-blocking-ndrg1-pre-mrna-maturation-study-reveals 2026-06-20T15:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rbm41-drives-colorectal-cancer-by-blocking-ndrg1-pre-mrna-maturation-study-reveals 2026-06-20T15:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/etomidate-laced-vaping-emerges-as-growing-threat-to-road-safety-in-singapore 2026-06-20T15:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/etomidate-laced-vaping-emerges-as-growing-threat-to-road-safety-in-singapore 2026-06-20T15:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-protein-nanocages-replicate-viral-self-assembly-opening-new-frontiers-in-drug-delivery 2026-06-20T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-protein-nanocages-replicate-viral-self-assembly-opening-new-frontiers-in-drug-delivery 2026-06-20T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/mars-to-launch-artificial-dye-free-m-m-s-in-august-amid-maha-push-blue-and-brown-colors-absent 2026-06-20T12:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mars-to-launch-artificial-dye-free-m-m-s-in-august-amid-maha-push-blue-and-brown-colors-absent 2026-06-20T12:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/usc-scientists-unlock-renewable-supply-of-cancer-fighting-immune-cells-via-gmp-platform 2026-06-20T12:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-scientists-unlock-renewable-supply-of-cancer-fighting-immune-cells-via-gmp-platform 2026-06-20T12:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-enables-durable-remission-in-adolescent-with-relapsed-lymphoma-a-singapore-case-study 2026-06-20T11:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-enables-durable-remission-in-adolescent-with-relapsed-lymphoma-a-singapore-case-study 2026-06-20T11:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-team-develops-gel-delivery-method-to-keep-colorectal-cancer-therapy-localized 2026-06-20T11:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-team-develops-gel-delivery-method-to-keep-colorectal-cancer-therapy-localized 2026-06-20T11:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/india-bans-16-fixed-dose-combination-drugs-over-safety-and-efficacy-concerns 2026-06-20T11:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-bans-16-fixed-dose-combination-drugs-over-safety-and-efficacy-concerns 2026-06-20T11:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-nears-10-9-billion-acquisition-of-apogee-therapeutics-for-long-acting-atopic-dermatitis-drug 2026-06-20T10:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-nears-10-9-billion-acquisition-of-apogee-therapeutics-for-long-acting-atopic-dermatitis-drug 2026-06-20T10:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/greenstone-biosciences-and-intel-launch-strategic-collaboration-to-scale-ai-enabled-human-centric-drug-discovery 2026-06-20T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenstone-biosciences-and-intel-launch-strategic-collaboration-to-scale-ai-enabled-human-centric-drug-discovery 2026-06-20T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/the-hidden-risks-of-dietary-supplements-rising-cases-of-liver-and-kidney-damage-prompt-expert-warnings 2026-06-20T05:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-hidden-risks-of-dietary-supplements-rising-cases-of-liver-and-kidney-damage-prompt-expert-warnings 2026-06-20T05:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/western-australia-launches-2-million-cardiovascular-research-fellowship-partnership 2026-06-20T04:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/western-australia-launches-2-million-cardiovascular-research-fellowship-partnership 2026-06-20T04:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/ndsu-and-sanford-health-launch-real-world-study-tracking-glp-1-effects-beyond-weight-loss 2026-06-20T03:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ndsu-and-sanford-health-launch-real-world-study-tracking-glp-1-effects-beyond-weight-loss 2026-06-20T03:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/unapproved-retatrutide-vials-found-with-double-the-labeled-dose-sparking-overdose-warnings 2026-06-20T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unapproved-retatrutide-vials-found-with-double-the-labeled-dose-sparking-overdose-warnings 2026-06-20T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-advances-ion775-into-phase-2-trial-for-hypertriglyceridemia 2026-06-20T01:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-pharmaceuticals-advances-ion775-into-phase-2-trial-for-hypertriglyceridemia 2026-06-20T01:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/disrupted-neuronal-microexons-drive-hyperarousal-via-camp-signaling-zebrafish-study-reveals 2026-06-20T01:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disrupted-neuronal-microexons-drive-hyperarousal-via-camp-signaling-zebrafish-study-reveals 2026-06-20T01:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-coffee-consumption-to-metabolic-health-and-sex-hormones 2026-06-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-coffee-consumption-to-metabolic-health-and-sex-hormones 2026-06-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-systems-redefine-pharmacy-workforce-skills-for-an-era-of-complex-care-and-ai-integration 2026-06-19T23:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-systems-redefine-pharmacy-workforce-skills-for-an-era-of-complex-care-and-ai-integration 2026-06-19T23:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/ai-assisted-volumetric-response-criteria-outperform-mrecist-in-pleural-mesothelioma-assessment 2026-06-19T23:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-assisted-volumetric-response-criteria-outperform-mrecist-in-pleural-mesothelioma-assessment 2026-06-19T23:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-engineered-immune-cells-show-promise-in-cancer-treatment-turkish-research-center-reveals-novel-immunotherapy-approach 2026-06-19T23:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-engineered-immune-cells-show-promise-in-cancer-treatment-turkish-research-center-reveals-novel-immunotherapy-approach 2026-06-19T23:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/professor-mohamed-shamji-assumes-eaaci-presidency-as-congress-2026-concludes-with-vision-zero-momentum 2026-06-19T23:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/professor-mohamed-shamji-assumes-eaaci-presidency-as-congress-2026-concludes-with-vision-zero-momentum 2026-06-19T23:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/nyra-medical-wins-2026-jon-dehaan-foundation-award-for-novel-mitral-valve-repair-technology 2026-06-19T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyra-medical-wins-2026-jon-dehaan-foundation-award-for-novel-mitral-valve-repair-technology 2026-06-19T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/niagara-region-and-niagara-health-launch-joint-physician-recruitment-partnership-to-address-critical-shortages 2026-06-19T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niagara-region-and-niagara-health-launch-joint-physician-recruitment-partnership-to-address-critical-shortages 2026-06-19T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/risk-analysis-index-outperforms-traditional-metrics-in-predicting-mortality-after-distal-femur-fracture-surgery 2026-06-19T21:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risk-analysis-index-outperforms-traditional-metrics-in-predicting-mortality-after-distal-femur-fracture-surgery 2026-06-19T21:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/st-bernards-becomes-first-in-northeast-arkansas-to-offer-lutathera-targeted-radiotherapy-for-rare-neuroendocrine-tumors 2026-06-19T20:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-bernards-becomes-first-in-northeast-arkansas-to-offer-lutathera-targeted-radiotherapy-for-rare-neuroendocrine-tumors 2026-06-19T20:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/deep-learning-uncovers-antimicrobial-peptides-hidden-within-prion-proteins 2026-06-19T20:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-learning-uncovers-antimicrobial-peptides-hidden-within-prion-proteins 2026-06-19T20:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/lrp5-protein-identified-as-novel-target-for-safer-antithrombotic-therapies-with-reduced-bleeding-risk 2026-06-19T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lrp5-protein-identified-as-novel-target-for-safer-antithrombotic-therapies-with-reduced-bleeding-risk 2026-06-19T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/dutchess-county-declares-public-safety-emergency-after-17-suspected-overdoses-in-72-hours-including-two-fatalities 2026-06-19T18:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dutchess-county-declares-public-safety-emergency-after-17-suspected-overdoses-in-72-hours-including-two-fatalities 2026-06-19T18:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-heart-failure-drugs-protect-cardiac-function-during-cancer-therapy 2026-06-19T18:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-heart-failure-drugs-protect-cardiac-function-during-cancer-therapy 2026-06-19T18:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/three-nejm-trials-challenge-routine-use-of-advanced-imaging-in-coronary-stent-procedures 2026-06-19T18:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-nejm-trials-challenge-routine-use-of-advanced-imaging-in-coronary-stent-procedures 2026-06-19T18:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-posts-record-quarter-targets-1-billion-revenue-on-ai-powered-multi-cancer-early-detection 2026-06-19T18:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-posts-record-quarter-targets-1-billion-revenue-on-ai-powered-multi-cancer-early-detection 2026-06-19T18:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-proteomics-maps-protein-distribution-across-the-human-body-and-cancers-opening-new-avenues-for-precision-oncology 2026-06-19T18:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-proteomics-maps-protein-distribution-across-the-human-body-and-cancers-opening-new-avenues-for-precision-oncology 2026-06-19T18:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/dea-acknowledges-cannabis-s-medical-benefits-and-relative-safety-at-rescheduling-hearing 2026-06-19T18:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-acknowledges-cannabis-s-medical-benefits-and-relative-safety-at-rescheduling-hearing 2026-06-19T18:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/federal-funding-cuts-compound-trial-complexity-at-clinical-research-sites-wcg-2025-report-reveals 2026-06-19T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-funding-cuts-compound-trial-complexity-at-clinical-research-sites-wcg-2025-report-reveals 2026-06-19T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/hypophosphatasia-market-poised-for-robust-growth-through-2036-as-next-generation-therapies-advance 2026-06-19T18:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypophosphatasia-market-poised-for-robust-growth-through-2036-as-next-generation-therapies-advance 2026-06-19T18:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/star-trial-demonstrates-trauma-focused-cbt-is-safe-and-effective-for-ptsd-in-patients-with-psychosis-challenging-decades-of-clinical-exclusion 2026-06-19T18:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/star-trial-demonstrates-trauma-focused-cbt-is-safe-and-effective-for-ptsd-in-patients-with-psychosis-challenging-decades-of-clinical-exclusion 2026-06-19T18:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/author-correction-issued-for-mage-a4-mage-a8-targeted-tcr-based-bispecific-t-cell-engager-study 2026-06-19T18:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/author-correction-issued-for-mage-a4-mage-a8-targeted-tcr-based-bispecific-t-cell-engager-study 2026-06-19T18:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulators-approve-modified-pathways-trial-protocol-with-minimum-age-of-11-for-puberty-blocker-study 2026-06-19T18:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-regulators-approve-modified-pathways-trial-protocol-with-minimum-age-of-11-for-puberty-blocker-study 2026-06-19T18:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/msk-advances-prostate-cancer-care-with-hifu-radiopharmaceuticals-and-precision-surgery-to-reduce-deaths-and-preserve-function 2026-06-19T17:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msk-advances-prostate-cancer-care-with-hifu-radiopharmaceuticals-and-precision-surgery-to-reduce-deaths-and-preserve-function 2026-06-19T17:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/rethinking-the-dmta-cycle-how-ai-automation-and-integration-are-reshaping-drug-discovery 2026-06-19T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rethinking-the-dmta-cycle-how-ai-automation-and-integration-are-reshaping-drug-discovery 2026-06-19T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/first-confirmed-bourbon-virus-case-in-new-york-highlights-diagnostic-challenges-of-emerging-tickborne-disease 2026-06-19T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-confirmed-bourbon-virus-case-in-new-york-highlights-diagnostic-challenges-of-emerging-tickborne-disease 2026-06-19T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/barts-health-tops-uk-nhs-commercial-trial-recruitment-for-seventh-consecutive-year 2026-06-19T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barts-health-tops-uk-nhs-commercial-trial-recruitment-for-seventh-consecutive-year 2026-06-19T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/vonoprazan-doxycycline-dual-therapy-matches-amoxicillin-regimen-for-h-pylori-eradication 2026-06-19T16:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vonoprazan-doxycycline-dual-therapy-matches-amoxicillin-regimen-for-h-pylori-eradication 2026-06-19T16:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/r2-retrotransposons-enable-efficient-dsb-free-gene-insertion-into-plant-genomes 2026-06-19T16:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r2-retrotransposons-enable-efficient-dsb-free-gene-insertion-into-plant-genomes 2026-06-19T16:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/oncologists-urge-women-over-50-to-consider-low-dose-ct-scans-for-lung-cancer-screening 2026-06-19T15:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncologists-urge-women-over-50-to-consider-low-dose-ct-scans-for-lung-cancer-screening 2026-06-19T15:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/institut-pasteur-korea-and-institut-pasteur-sign-new-agreement-to-deepen-strategic-collaboration 2026-06-19T15:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/institut-pasteur-korea-and-institut-pasteur-sign-new-agreement-to-deepen-strategic-collaboration 2026-06-19T15:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/uconn-health-researcher-awarded-20000-grant-to-study-molecular-basis-of-hao-fountain-syndrome 2026-06-19T14:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uconn-health-researcher-awarded-20000-grant-to-study-molecular-basis-of-hao-fountain-syndrome 2026-06-19T14:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/openai-s-healthcare-push-gpt-5-5-instant-outperforms-physicians-in-healthbench-consumer-tool-faces-scrutiny 2026-06-19T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openai-s-healthcare-push-gpt-5-5-instant-outperforms-physicians-in-healthbench-consumer-tool-faces-scrutiny 2026-06-19T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/south-african-scientists-decode-how-cancer-rewires-muc1-sugar-coating-to-evade-the-immune-system 2026-06-19T14:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-african-scientists-decode-how-cancer-rewires-muc1-sugar-coating-to-evade-the-immune-system 2026-06-19T14:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/liver-targeted-lentiviral-gene-therapy-shows-safety-and-efficacy-in-preclinical-arc-syndrome-model 2026-06-19T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-targeted-lentiviral-gene-therapy-shows-safety-and-efficacy-in-preclinical-arc-syndrome-model 2026-06-19T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-multiomics-market-to-surge-from-2-99-billion-to-18-20-billion-by-2035-driven-by-precision-medicine-and-ai 2026-06-19T14:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-multiomics-market-to-surge-from-2-99-billion-to-18-20-billion-by-2035-driven-by-precision-medicine-and-ai 2026-06-19T14:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/blood-brain-barrier-crossing-antihypertensives-linked-to-lower-dementia-and-mortality-risk 2026-06-19T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-brain-barrier-crossing-antihypertensives-linked-to-lower-dementia-and-mortality-risk 2026-06-19T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/oct-biomarkers-distinguish-progression-to-neovascular-vs-atrophic-amd-in-intermediate-disease 2026-06-19T12:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oct-biomarkers-distinguish-progression-to-neovascular-vs-atrophic-amd-in-intermediate-disease 2026-06-19T12:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-drug-price-negotiation-program-takes-effect-10-common-drugs-see-list-price-cuts-of-38-to-79-in-2026 2026-06-19T11:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-drug-price-negotiation-program-takes-effect-10-common-drugs-see-list-price-cuts-of-38-to-79-in-2026 2026-06-19T11:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/midjourney-enters-medicine-with-full-body-ultrasound-scanner-betting-on-data-over-diagnostics 2026-06-19T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/midjourney-enters-medicine-with-full-body-ultrasound-scanner-betting-on-data-over-diagnostics 2026-06-19T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/teijin-and-merz-secure-japanese-approval-for-xeomin-r-in-cervical-dystonia-and-blepharospasm 2026-06-19T09:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teijin-and-merz-secure-japanese-approval-for-xeomin-r-in-cervical-dystonia-and-blepharospasm 2026-06-19T09:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/temple-s-entropy-biomarker-claim-sparks-debate-wearable-startup-promises-real-time-metabolic-scoring-doctors-demand-evidence 2026-06-19T07:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/temple-s-entropy-biomarker-claim-sparks-debate-wearable-startup-promises-real-time-metabolic-scoring-doctors-demand-evidence 2026-06-19T07:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/malaysian-re-and-china-re-life-sign-landmark-reinsurance-treaty-for-cancer-precision-medicine-coverage-in-malaysia 2026-06-19T07:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysian-re-and-china-re-life-sign-landmark-reinsurance-treaty-for-cancer-precision-medicine-coverage-in-malaysia 2026-06-19T07:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/senate-help-committee-advances-two-biosimilar-reform-bills-to-accelerate-patient-access-to-lower-cost-medicines 2026-06-19T06:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-help-committee-advances-two-biosimilar-reform-bills-to-accelerate-patient-access-to-lower-cost-medicines 2026-06-19T06:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/biotns-to-lead-19-5m-south-korean-government-program-for-ultra-precision-digital-pcr-standards 2026-06-19T03:53:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotns-to-lead-19-5m-south-korean-government-program-for-ultra-precision-digital-pcr-standards 2026-06-19T03:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/queensland-awards-7-7-million-to-bioora-for-onshore-car-t-cell-manufacturing-facility 2026-06-19T03:53:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queensland-awards-7-7-million-to-bioora-for-onshore-car-t-cell-manufacturing-facility 2026-06-19T03:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/embecta-faces-securities-class-action-over-alleged-misrepresentation-of-insulin-pen-needle-demand-58-stock-drop 2026-06-19T03:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embecta-faces-securities-class-action-over-alleged-misrepresentation-of-insulin-pen-needle-demand-58-stock-drop 2026-06-19T03:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/rotavirus-vaccine-cuts-rotavirus-positive-gastroenteritis-deaths-by-nearly-76-in-global-study 2026-06-19T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rotavirus-vaccine-cuts-rotavirus-positive-gastroenteritis-deaths-by-nearly-76-in-global-study 2026-06-19T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/web-of-biological-data-act-bipartisan-bill-seeks-to-centralize-u-s-biological-data-to-accelerate-biotech-innovation 2026-06-19T01:53:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/web-of-biological-data-act-bipartisan-bill-seeks-to-centralize-u-s-biological-data-to-accelerate-biotech-innovation 2026-06-19T01:53:20+00:00 hourly 0.9 https://trial.medpath.com/news/activity-dependent-antioxidant-gene-therapy-shows-promise-in-suppressing-epileptogenesis 2026-06-19T01:53:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/activity-dependent-antioxidant-gene-therapy-shows-promise-in-suppressing-epileptogenesis 2026-06-19T01:53:19+00:00 hourly 0.9 https://trial.medpath.com/news/lab-on-a-chip-platform-celltrap-reveals-how-single-immune-cells-attack-brain-tumors-in-real-time 2026-06-19T01:52:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lab-on-a-chip-platform-celltrap-reveals-how-single-immune-cells-attack-brain-tumors-in-real-time 2026-06-19T01:52:53+00:00 hourly 0.9 https://trial.medpath.com/news/proscia-launches-fifth-generation-concentriq-platform-embedding-multimodal-ai-into-digital-pathology 2026-06-19T01:51:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proscia-launches-fifth-generation-concentriq-platform-embedding-multimodal-ai-into-digital-pathology 2026-06-19T01:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/colorectal-cancer-rising-in-younger-adults-surgeons-urge-awareness-of-subtle-warning-signs 2026-06-19T01:51:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorectal-cancer-rising-in-younger-adults-surgeons-urge-awareness-of-subtle-warning-signs 2026-06-19T01:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/liver-cancer-deaths-surge-experts-call-for-urgent-policy-action-as-60-of-cases-prove-preventable 2026-06-19T01:51:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-cancer-deaths-surge-experts-call-for-urgent-policy-action-as-60-of-cases-prove-preventable 2026-06-19T01:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/her2-ladder-a-spatially-interpretable-ai-framework-predicts-neoadjuvant-dual-her2-targeted-therapy-response-in-breast-cancer 2026-06-19T01:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her2-ladder-a-spatially-interpretable-ai-framework-predicts-neoadjuvant-dual-her2-targeted-therapy-response-in-breast-cancer 2026-06-19T01:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/creatine-emerges-as-a-standout-supplement-for-women-s-muscle-metabolic-and-cognitive-health 2026-06-19T01:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creatine-emerges-as-a-standout-supplement-for-women-s-muscle-metabolic-and-cognitive-health 2026-06-19T01:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-surges-to-record-high-on-strong-q2-2026-earnings 2026-06-19T00:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-surges-to-record-high-on-strong-q2-2026-earnings 2026-06-19T00:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/neuro-immune-interactions-in-cancer-emerging-therapeutic-strategies-target-the-neural-addiction-of-tumors 2026-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuro-immune-interactions-in-cancer-emerging-therapeutic-strategies-target-the-neural-addiction-of-tumors 2026-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/older-exercise-instructors-bridge-generational-gap-boosting-physical-activity-adherence-among-seniors 2026-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/older-exercise-instructors-bridge-generational-gap-boosting-physical-activity-adherence-among-seniors 2026-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cholinergic-regulation-of-neuroinflammation-microglia-immunometabolism-and-therapeutic-frontiers 2026-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cholinergic-regulation-of-neuroinflammation-microglia-immunometabolism-and-therapeutic-frontiers 2026-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/florida-s-aids-drug-assistance-program-faces-renewed-funding-crisis-despite-legislative-rescue 2026-06-18T23:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-s-aids-drug-assistance-program-faces-renewed-funding-crisis-despite-legislative-rescue 2026-06-18T23:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/extreme-heat-at-2026-fifa-world-cup-poses-serious-health-risks-to-fans-and-workers-experts-warn 2026-06-18T23:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extreme-heat-at-2026-fifa-world-cup-poses-serious-health-risks-to-fans-and-workers-experts-warn 2026-06-18T23:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/sl-science-advances-allogeneic-gamma-delta-t-cell-platform-toward-ind-reports-2025-financial-results-following-nasdaq-listing 2026-06-18T22:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sl-science-advances-allogeneic-gamma-delta-t-cell-platform-toward-ind-reports-2025-financial-results-following-nasdaq-listing 2026-06-18T22:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/rural-pharmacy-closures-accelerate-threatening-healthcare-access-for-millions-of-americans 2026-06-18T22:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rural-pharmacy-closures-accelerate-threatening-healthcare-access-for-millions-of-americans 2026-06-18T22:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-testing-emerges-as-critical-tool-in-lung-cancer-treatment-experts-urge-patients-to-advocate-for-comprehensive-testing 2026-06-18T21:44:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-testing-emerges-as-critical-tool-in-lung-cancer-treatment-experts-urge-patients-to-advocate-for-comprehensive-testing 2026-06-18T21:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-declares-1-73-quarterly-dividend-extending-13-year-track-record-of-payout-growth 2026-06-18T21:44:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-declares-1-73-quarterly-dividend-extending-13-year-track-record-of-payout-growth 2026-06-18T21:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/financial-toxicity-in-australia-s-cancer-care-patients-turn-to-crowdfunding-amid-growing-out-of-pocket-costs 2026-06-18T21:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/financial-toxicity-in-australia-s-cancer-care-patients-turn-to-crowdfunding-amid-growing-out-of-pocket-costs 2026-06-18T21:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/michael-j-fox-foundation-unveils-redesigned-educational-resources-to-accelerate-parkinson-s-community-engagement 2026-06-18T21:44:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michael-j-fox-foundation-unveils-redesigned-educational-resources-to-accelerate-parkinson-s-community-engagement 2026-06-18T21:44:03+00:00 hourly 0.9 https://trial.medpath.com/news/ai-s-growing-energy-and-water-demands-pose-overlooked-public-health-risks-experts-warn 2026-06-18T21:43:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-s-growing-energy-and-water-demands-pose-overlooked-public-health-risks-experts-warn 2026-06-18T21:43:46+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-cuts-340b-drug-discounts-to-noncompliant-hospitals-sparking-legal-backlash 2026-06-18T21:43:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-cuts-340b-drug-discounts-to-noncompliant-hospitals-sparking-legal-backlash 2026-06-18T21:43:42+00:00 hourly 0.9 https://trial.medpath.com/news/wright-state-s-madhavi-kadakia-honored-by-aamc-for-national-research-leadership 2026-06-18T21:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wright-state-s-madhavi-kadakia-honored-by-aamc-for-national-research-leadership 2026-06-18T21:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/whole-genome-sequencing-moves-into-clinical-care-for-critically-ill-children 2026-06-18T21:42:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whole-genome-sequencing-moves-into-clinical-care-for-critically-ill-children 2026-06-18T21:42:48+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-deskilling-in-medicine-evidence-mounts-that-clinicians-lose-diagnostic-abilities-when-relying-on-artificial-intelligence 2026-06-18T20:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-deskilling-in-medicine-evidence-mounts-that-clinicians-lose-diagnostic-abilities-when-relying-on-artificial-intelligence 2026-06-18T20:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-acne-vaccine-enters-early-clinical-trials-as-sanofi-and-armora-biosciences-pursue-preventive-approaches 2026-06-18T20:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-acne-vaccine-enters-early-clinical-trials-as-sanofi-and-armora-biosciences-pursue-preventive-approaches 2026-06-18T20:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/blood-cancer-s-genetic-warning-signs-may-appear-years-before-diagnosis-landmark-study-reveals 2026-06-18T20:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-cancer-s-genetic-warning-signs-may-appear-years-before-diagnosis-landmark-study-reveals 2026-06-18T20:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/milken-institute-and-ann-theodore-foundation-award-600000-to-early-career-sarcoidosis-researchers-launch-second-funding-cycle 2026-06-18T20:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milken-institute-and-ann-theodore-foundation-award-600000-to-early-career-sarcoidosis-researchers-launch-second-funding-cycle 2026-06-18T20:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/dante-labs-technology-powers-over-100-global-scientific-studies-spanning-rare-diseases-oncology-and-crispr-gene-editing 2026-06-18T20:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dante-labs-technology-powers-over-100-global-scientific-studies-spanning-rare-diseases-oncology-and-crispr-gene-editing 2026-06-18T20:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/product-development-partnerships-a-proven-model-for-delivering-innovation-in-global-health-reform 2026-06-18T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/product-development-partnerships-a-proven-model-for-delivering-innovation-in-global-health-reform 2026-06-18T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-requires-aurobindo-to-divest-four-generic-drugs-to-protect-competition-in-250-million-lannett-acquisition 2026-06-18T20:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-requires-aurobindo-to-divest-four-generic-drugs-to-protect-competition-in-250-million-lannett-acquisition 2026-06-18T20:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-glp-1-bridge-pilot-program-to-cap-weight-loss-drug-costs-at-50-per-month 2026-06-18T20:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-glp-1-bridge-pilot-program-to-cap-weight-loss-drug-costs-at-50-per-month 2026-06-18T20:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/myxobacteria-biodiversity-boom-118-new-strains-yield-five-novel-antibiotic-classes-against-multidrug-resistant-pathogens 2026-06-18T20:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myxobacteria-biodiversity-boom-118-new-strains-yield-five-novel-antibiotic-classes-against-multidrug-resistant-pathogens 2026-06-18T20:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/gundry-md-launches-elevate-nad-nmn-supplement-with-patent-pending-beadlet-technology-targets-age-related-nad-decline 2026-06-18T19:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gundry-md-launches-elevate-nad-nmn-supplement-with-patent-pending-beadlet-technology-targets-age-related-nad-decline 2026-06-18T19:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-healthcare-affordability-hits-five-year-low-fewer-than-half-of-adults-now-cost-secure 2026-06-18T19:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-healthcare-affordability-hits-five-year-low-fewer-than-half-of-adults-now-cost-secure 2026-06-18T19:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-receives-40-million-nih-ctsa-award-to-accelerate-clinical-translation 2026-06-18T19:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-receives-40-million-nih-ctsa-award-to-accelerate-clinical-translation 2026-06-18T19:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-selects-seven-companies-for-precheck-pilot-program-to-boost-domestic-drug-manufacturing 2026-06-18T19:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-selects-seven-companies-for-precheck-pilot-program-to-boost-domestic-drug-manufacturing 2026-06-18T19:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/extended-low-dose-apixaban-cuts-recurrent-vte-in-high-risk-provoked-patients 2026-06-18T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-low-dose-apixaban-cuts-recurrent-vte-in-high-risk-provoked-patients 2026-06-18T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/cardio-diagnostics-advances-ai-powered-precision-cardiovascular-medicine-platform 2026-06-18T19:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardio-diagnostics-advances-ai-powered-precision-cardiovascular-medicine-platform 2026-06-18T19:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/massive-uk-biobank-study-finds-wine-drinkers-face-lower-mortality-risk-than-beer-or-spirits-consumers 2026-06-18T19:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-uk-biobank-study-finds-wine-drinkers-face-lower-mortality-risk-than-beer-or-spirits-consumers 2026-06-18T19:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-ketamine-buprenorphine-combination-sustains-anti-suicidal-effects-reviving-the-opioid-hypothesis-of-depression 2026-06-18T18:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-ketamine-buprenorphine-combination-sustains-anti-suicidal-effects-reviving-the-opioid-hypothesis-of-depression 2026-06-18T18:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/first-preclinical-mrna-vaccine-for-neuroblastoma-shrinks-tumors-by-70-in-murine-models 2026-06-18T18:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-preclinical-mrna-vaccine-for-neuroblastoma-shrinks-tumors-by-70-in-murine-models 2026-06-18T18:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-map-of-bladder-cancer-reveals-hidden-tumor-environments-and-new-paths-toward-precision-therapy 2026-06-18T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-map-of-bladder-cancer-reveals-hidden-tumor-environments-and-new-paths-toward-precision-therapy 2026-06-18T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/the-ottawa-hospital-s-biotherapeutics-manufacturing-centre-rebrands-as-boreal-biomanufacturing-plans-major-expansion 2026-06-18T18:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-ottawa-hospital-s-biotherapeutics-manufacturing-centre-rebrands-as-boreal-biomanufacturing-plans-major-expansion 2026-06-18T18:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-foundation-of-santa-barbara-awards-95000-to-local-pediatric-cancer-programs 2026-06-18T18:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-foundation-of-santa-barbara-awards-95000-to-local-pediatric-cancer-programs 2026-06-18T18:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-variant-linked-to-onion-preference-associated-with-lower-blood-pressure-and-reduced-type-2-diabetes-risk 2026-06-18T18:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-variant-linked-to-onion-preference-associated-with-lower-blood-pressure-and-reduced-type-2-diabetes-risk 2026-06-18T18:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/sunscreen-misinformation-on-tiktok-outperforms-evidence-based-content-study-finds 2026-06-18T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunscreen-misinformation-on-tiktok-outperforms-evidence-based-content-study-finds 2026-06-18T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/rgcb-scientists-uncover-host-cell-mechanism-behind-malaria-parasite-s-artemisinin-tolerance 2026-06-18T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rgcb-scientists-uncover-host-cell-mechanism-behind-malaria-parasite-s-artemisinin-tolerance 2026-06-18T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/single-use-support-launches-next-generation-ross-blst-blast-freezer-with-recipe-driven-80degc-protocols-for-biopharmaceutical-cold-chain 2026-06-18T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-use-support-launches-next-generation-ross-blst-blast-freezer-with-recipe-driven-80degc-protocols-for-biopharmaceutical-cold-chain 2026-06-18T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/preserving-data-quality-in-early-stage-alzheimer-s-trials-aligning-endpoint-strategy-rater-training-and-ecoa-delivery 2026-06-18T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preserving-data-quality-in-early-stage-alzheimer-s-trials-aligning-endpoint-strategy-rater-training-and-ecoa-delivery 2026-06-18T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-launches-25-million-corporate-venture-fund-to-accelerate-animal-health-innovation 2026-06-18T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elanco-launches-25-million-corporate-venture-fund-to-accelerate-animal-health-innovation 2026-06-18T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/nortiva-bio-launches-as-clinical-stage-company-to-develop-long-acting-oral-medicines-using-lynxtm-platform 2026-06-18T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nortiva-bio-launches-as-clinical-stage-company-to-develop-long-acting-oral-medicines-using-lynxtm-platform 2026-06-18T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathic-pulmonary-fibrosis 2026-06-18T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathic-pulmonary-fibrosis 2026-06-18T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/nanomedicine-driven-precision-therapy-for-renal-fibrosis-bridging-molecular-mechanisms-and-targeted-delivery 2026-06-18T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanomedicine-driven-precision-therapy-for-renal-fibrosis-bridging-molecular-mechanisms-and-targeted-delivery 2026-06-18T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-receives-fda-clearance-for-beam-304-a-first-in-class-in-vivo-base-editing-therapy-for-phenylketonuria 2026-06-18T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-receives-fda-clearance-for-beam-304-a-first-in-class-in-vivo-base-editing-therapy-for-phenylketonuria 2026-06-18T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/global-snap-trial-finds-cefazolin-safer-and-equally-effective-as-flucloxacillin-for-mssa-bloodstream-infections 2026-06-18T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-snap-trial-finds-cefazolin-safer-and-equally-effective-as-flucloxacillin-for-mssa-bloodstream-infections 2026-06-18T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-appoints-cecile-guegan-as-interim-cfo-as-dave-denton-departs-for-consumer-goods-role 2026-06-18T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-appoints-cecile-guegan-as-interim-cfo-as-dave-denton-departs-for-consumer-goods-role 2026-06-18T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/resilience-relocates-headquarters-from-san-diego-to-ohio-expands-sterile-injectable-manufacturing-capacity 2026-06-18T17:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resilience-relocates-headquarters-from-san-diego-to-ohio-expands-sterile-injectable-manufacturing-capacity 2026-06-18T17:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/statins-remain-lifesaving-evidence-based-therapy-despite-social-media-misinformation-cardiologists-affirm 2026-06-18T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-remain-lifesaving-evidence-based-therapy-despite-social-media-misinformation-cardiologists-affirm 2026-06-18T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phasewell-research-partners-with-latin-clinical-trial-center-to-expand-clinical-trial-access-in-puerto-rico 2026-06-18T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phasewell-research-partners-with-latin-clinical-trial-center-to-expand-clinical-trial-access-in-puerto-rico 2026-06-18T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/cour-pharma-closes-50-million-series-b-to-advance-first-in-class-immune-tolerance-therapy-for-type-1-diabetes 2026-06-18T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cour-pharma-closes-50-million-series-b-to-advance-first-in-class-immune-tolerance-therapy-for-type-1-diabetes 2026-06-18T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/matica-bio-launches-integrated-korea-iit-platform-to-accelerate-global-cell-and-gene-therapy-development 2026-06-18T16:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matica-bio-launches-integrated-korea-iit-platform-to-accelerate-global-cell-and-gene-therapy-development 2026-06-18T16:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/chiesi-global-rare-diseases-highlights-advancements-in-lipodystrophy-research-at-endo-2026 2026-06-18T15:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chiesi-global-rare-diseases-highlights-advancements-in-lipodystrophy-research-at-endo-2026 2026-06-18T15:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/openai-s-o3-model-helps-boston-children-s-hospital-diagnose-18-children-with-rare-diseases-that-had-eluded-experts 2026-06-18T15:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openai-s-o3-model-helps-boston-children-s-hospital-diagnose-18-children-with-rare-diseases-that-had-eluded-experts 2026-06-18T15:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-phase-3-trident-trial-misses-primary-survival-endpoint-in-newly-diagnosed-glioblastoma 2026-06-18T14:45:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-phase-3-trident-trial-misses-primary-survival-endpoint-in-newly-diagnosed-glioblastoma 2026-06-18T14:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/gandeeva-and-zymeworks-use-cryo-em-to-resolve-antibody-epitopes-on-flexible-antigens-at-near-atomic-resolution 2026-06-18T14:45:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gandeeva-and-zymeworks-use-cryo-em-to-resolve-antibody-epitopes-on-flexible-antigens-at-near-atomic-resolution 2026-06-18T14:45:03+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-iowa-researchers-secure-nearly-12-million-nih-grant-to-develop-gene-editing-treatments-for-primary-ciliary-dyskinesia 2026-06-18T14:44:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-iowa-researchers-secure-nearly-12-million-nih-grant-to-develop-gene-editing-treatments-for-primary-ciliary-dyskinesia 2026-06-18T14:44:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-reviews-moderna-s-mrna-based-influenza-vaccine-mflusiva-a-first-of-its-kind-shot-for-adults-50-and-older 2026-06-18T14:44:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-reviews-moderna-s-mrna-based-influenza-vaccine-mflusiva-a-first-of-its-kind-shot-for-adults-50-and-older 2026-06-18T14:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-clears-path-for-curium-s-lutetium-lu-177-dotatate-in-gep-nets-invalidating-novartis-patents 2026-06-18T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-court-clears-path-for-curium-s-lutetium-lu-177-dotatate-in-gep-nets-invalidating-novartis-patents 2026-06-18T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/blood-metabolome-study-links-ergothioneine-lifestyle-factors-to-midlife-brain-health-and-alzheimer-s-risk 2026-06-18T13:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-metabolome-study-links-ergothioneine-lifestyle-factors-to-midlife-brain-health-and-alzheimer-s-risk 2026-06-18T13:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/chemoenzymatic-ligation-emerges-as-scalable-solution-to-nucleic-acid-therapeutics-manufacturing-bottlenecks 2026-06-18T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemoenzymatic-ligation-emerges-as-scalable-solution-to-nucleic-acid-therapeutics-manufacturing-bottlenecks 2026-06-18T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/pramaana-labs-raises-27m-to-bring-formal-verification-to-ai-in-drug-discovery-and-medical-diagnosis 2026-06-18T13:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pramaana-labs-raises-27m-to-bring-formal-verification-to-ai-in-drug-discovery-and-medical-diagnosis 2026-06-18T13:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/six-taipei-biotechs-head-to-bio-2026-with-late-stage-assets-precision-diagnostics-and-next-generation-drug-delivery-platforms 2026-06-18T13:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-taipei-biotechs-head-to-bio-2026-with-late-stage-assets-precision-diagnostics-and-next-generation-drug-delivery-platforms 2026-06-18T13:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-showcases-allosure-dd-cfdna-as-emerging-clinical-endpoint-across-30-abstracts-at-atc-2026 2026-06-18T13:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-showcases-allosure-dd-cfdna-as-emerging-clinical-endpoint-across-30-abstracts-at-atc-2026 2026-06-18T13:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/health-technology-expands-access-to-care-through-telemedicine-ai-and-remote-monitoring 2026-06-18T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-technology-expands-access-to-care-through-telemedicine-ai-and-remote-monitoring 2026-06-18T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/unraveling-the-immune-metabolic-nexus-in-post-acute-infection-syndromes-a-new-research-frontier 2026-06-18T12:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unraveling-the-immune-metabolic-nexus-in-post-acute-infection-syndromes-a-new-research-frontier 2026-06-18T12:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/humoral-immunity-emerges-as-a-spatially-organized-state-dependent-axis-of-antitumor-defense-and-therapeutic-targeting 2026-06-18T11:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humoral-immunity-emerges-as-a-spatially-organized-state-dependent-axis-of-antitumor-defense-and-therapeutic-targeting 2026-06-18T11:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-enters-up-to-1-billion-agreement-to-acquire-raythera-expanding-immunology-pipeline-with-small-molecule-assets 2026-06-18T10:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-enters-up-to-1-billion-agreement-to-acquire-raythera-expanding-immunology-pipeline-with-small-molecule-assets 2026-06-18T10:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/former-child-star-daveigh-chase-dies-at-35-from-aids-related-complications-sepsis-and-meningitis-also-cited 2026-06-18T10:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-child-star-daveigh-chase-dies-at-35-from-aids-related-complications-sepsis-and-meningitis-also-cited 2026-06-18T10:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/parkinson-s-disease-four-silent-warning-signs-that-can-appear-years-before-diagnosis 2026-06-18T09:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parkinson-s-disease-four-silent-warning-signs-that-can-appear-years-before-diagnosis 2026-06-18T09:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbes-may-explain-why-obesity-and-type-2-diabetes-become-harder-to-reverse 2026-06-18T09:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbes-may-explain-why-obesity-and-type-2-diabetes-become-harder-to-reverse 2026-06-18T09:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/the-healing-sanctuary-a-grassroots-nonprofit-fills-the-survivorship-care-gap-for-akron-area-women-after-cancer 2026-06-18T09:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-healing-sanctuary-a-grassroots-nonprofit-fills-the-survivorship-care-gap-for-akron-area-women-after-cancer 2026-06-18T09:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/medical-cannabis-legalization-linked-to-6-9-drop-in-health-related-workplace-absenteeism 2026-06-18T09:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-cannabis-legalization-linked-to-6-9-drop-in-health-related-workplace-absenteeism 2026-06-18T09:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/computer-models-reveal-path-to-more-effective-probiotic-supplements-uva-study-finds 2026-06-18T09:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/computer-models-reveal-path-to-more-effective-probiotic-supplements-uva-study-finds 2026-06-18T09:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/fitness-trackers-and-smartphone-apps-boost-physical-activity-in-cardiovascular-disease-patients-meta-analysis-finds 2026-06-18T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fitness-trackers-and-smartphone-apps-boost-physical-activity-in-cardiovascular-disease-patients-meta-analysis-finds 2026-06-18T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncoinvent-reaches-50-recruitment-milestone-in-phase-2-ovarian-cancer-trial-of-alpha-emitting-radspherin 2026-06-18T08:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoinvent-reaches-50-recruitment-milestone-in-phase-2-ovarian-cancer-trial-of-alpha-emitting-radspherin 2026-06-18T08:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/umea-researchers-develop-fully-human-antibody-that-blocks-metastasis-in-aggressive-prostate-cancer 2026-06-18T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umea-researchers-develop-fully-human-antibody-that-blocks-metastasis-in-aggressive-prostate-cancer 2026-06-18T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-research-delivery-kpis-show-gains-in-trial-set-up-speed-but-persistent-gaps-in-study-opening 2026-06-18T06:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-clinical-research-delivery-kpis-show-gains-in-trial-set-up-speed-but-persistent-gaps-in-study-opening 2026-06-18T06:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/medical-plastics-market-projected-to-reach-usd-73-6-billion-by-2036-driven-by-disposable-healthcare-products-and-sustainability-innovation 2026-06-18T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-plastics-market-projected-to-reach-usd-73-6-billion-by-2036-driven-by-disposable-healthcare-products-and-sustainability-innovation 2026-06-18T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-faces-most-severe-medicine-shortages-on-record-posing-serious-patient-safety-risk 2026-06-18T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-faces-most-severe-medicine-shortages-on-record-posing-serious-patient-safety-risk 2026-06-18T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/chickadee-cohort-study-to-chart-kidney-and-cardiovascular-trajectories-in-children-after-congenital-heart-surgery 2026-06-18T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chickadee-cohort-study-to-chart-kidney-and-cardiovascular-trajectories-in-children-after-congenital-heart-surgery 2026-06-18T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptamer-sciences-trop2-apdc-selected-for-south-korea-s-national-new-drug-development-project 2026-06-18T02:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptamer-sciences-trop2-apdc-selected-for-south-korea-s-national-new-drug-development-project 2026-06-18T02:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/washu-researchers-identify-shared-achilles-heel-of-etec-and-shigella-paving-way-for-a-universal-diarrhea-vaccine 2026-06-18T02:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/washu-researchers-identify-shared-achilles-heel-of-etec-and-shigella-paving-way-for-a-universal-diarrhea-vaccine 2026-06-18T02:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-sends-promising-ebola-monoclonal-antibody-mbp-134-for-clinical-trial-amid-growing-drc-outbreak 2026-06-18T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-sends-promising-ebola-monoclonal-antibody-mbp-134-for-clinical-trial-amid-growing-drc-outbreak 2026-06-18T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/accenture-to-acquire-alfahealth-expanding-ai-powered-digital-health-capabilities-across-italy 2026-06-18T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accenture-to-acquire-alfahealth-expanding-ai-powered-digital-health-capabilities-across-italy 2026-06-18T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-shows-safety-and-early-efficacy-signals-in-friedreich-ataxia-cardiomyopathy-phase-1-trial 2026-06-18T00:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-therapy-shows-safety-and-early-efficacy-signals-in-friedreich-ataxia-cardiomyopathy-phase-1-trial 2026-06-18T00:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/preoperative-radiation-therapy-reshapes-immune-microenvironment-in-brain-metastases-opening-door-to-immunotherapy-combinations 2026-06-18T00:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preoperative-radiation-therapy-reshapes-immune-microenvironment-in-brain-metastases-opening-door-to-immunotherapy-combinations 2026-06-18T00:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-adopts-all-resolutions-at-2026-annual-general-meeting-amid-strategic-out-licensing-push 2026-06-18T00:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-adopts-all-resolutions-at-2026-annual-general-meeting-amid-strategic-out-licensing-push 2026-06-18T00:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/cardio-oncology-collaboration-essential-for-protecting-heart-health-during-and-after-cancer-treatment-thedacare-experts-advise 2026-06-17T23:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardio-oncology-collaboration-essential-for-protecting-heart-health-during-and-after-cancer-treatment-thedacare-experts-advise 2026-06-17T23:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-officials-outline-ai-and-real-world-evidence-integration-strategy-at-dia-global-annual-meeting 2026-06-17T23:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-officials-outline-ai-and-real-world-evidence-integration-strategy-at-dia-global-annual-meeting 2026-06-17T23:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/oregon-advocates-push-for-2027-legislation-mandating-insurance-coverage-of-biomarker-testing 2026-06-17T23:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oregon-advocates-push-for-2027-legislation-mandating-insurance-coverage-of-biomarker-testing 2026-06-17T23:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/plastic-chemical-dehp-rewires-fetal-brain-anxiety-circuits-via-gaba-study-shows 2026-06-17T23:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plastic-chemical-dehp-rewires-fetal-brain-anxiety-circuits-via-gaba-study-shows 2026-06-17T23:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-warns-of-critical-shortage-of-stereotactic-breast-biopsy-needles-following-hologic-recall-disruption-expected-through-march-2027 2026-06-17T22:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-warns-of-critical-shortage-of-stereotactic-breast-biopsy-needles-following-hologic-recall-disruption-expected-through-march-2027 2026-06-17T22:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/medivir-raises-sek-130-million-to-advance-miv-711-as-first-pharmacological-treatment-for-pediatric-perthes-disease 2026-06-17T22:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medivir-raises-sek-130-million-to-advance-miv-711-as-first-pharmacological-treatment-for-pediatric-perthes-disease 2026-06-17T22:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-redesignated-as-who-collaborating-centre-for-childhood-cancer-expanding-global-pediatric-oncology-efforts 2026-06-17T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-jude-redesignated-as-who-collaborating-centre-for-childhood-cancer-expanding-global-pediatric-oncology-efforts 2026-06-17T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-misinformation-is-deadly-alternative-treatments-linked-to-2-to-5-6-fold-higher-mortality 2026-06-17T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-misinformation-is-deadly-alternative-treatments-linked-to-2-to-5-6-fold-higher-mortality 2026-06-17T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/soluble-her2-drives-cd8-t-cell-exhaustion-and-limits-immunotherapy-response-in-her2-low-triple-negative-breast-cancer 2026-06-17T21:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soluble-her2-drives-cd8-t-cell-exhaustion-and-limits-immunotherapy-response-in-her2-low-triple-negative-breast-cancer 2026-06-17T21:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-amie-ai-system-matches-physicians-in-long-term-disease-management-nature-study-finds 2026-06-17T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-amie-ai-system-matches-physicians-in-long-term-disease-management-nature-study-finds 2026-06-17T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/naegleria-fowleri-understanding-the-rare-brain-eating-amoeba-and-emerging-treatment-advances 2026-06-17T21:02:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naegleria-fowleri-understanding-the-rare-brain-eating-amoeba-and-emerging-treatment-advances 2026-06-17T21:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/us-biomedical-research-funding-crisis-threatens-a-generation-of-scientists 2026-06-17T21:02:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-biomedical-research-funding-crisis-threatens-a-generation-of-scientists 2026-06-17T21:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printing-medical-devices-market-poised-to-reach-18-61-billion-by-2035-driven-by-personalized-implants-and-surgical-innovation 2026-06-17T21:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-printing-medical-devices-market-poised-to-reach-18-61-billion-by-2035-driven-by-personalized-implants-and-surgical-innovation 2026-06-17T21:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-neuropsychiatric-drug-discovery-promise-and-persistent-challenges-in-a-lagging-field 2026-06-17T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-in-neuropsychiatric-drug-discovery-promise-and-persistent-challenges-in-a-lagging-field 2026-06-17T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/genicular-artery-embolization-with-resorbable-microspheres-delivers-lasting-knee-osteoarthritis-pain-relief-study-shows 2026-06-17T21:01:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genicular-artery-embolization-with-resorbable-microspheres-delivers-lasting-knee-osteoarthritis-pain-relief-study-shows 2026-06-17T21:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/unaids-warns-of-perilous-moment-as-funding-cuts-threaten-to-reverse-decades-of-hiv-aids-progress 2026-06-17T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unaids-warns-of-perilous-moment-as-funding-cuts-threaten-to-reverse-decades-of-hiv-aids-progress 2026-06-17T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/greater-manchester-secures-ps50m-ukri-innovation-funding-backing-health-data-wearables-and-ai-driven-life-sciences-projects 2026-06-17T19:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greater-manchester-secures-ps50m-ukri-innovation-funding-backing-health-data-wearables-and-ai-driven-life-sciences-projects 2026-06-17T19:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/genomics-giant-illumina-taps-veteran-life-sciences-lawyer-as-general-counsel 2026-06-17T19:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomics-giant-illumina-taps-veteran-life-sciences-lawyer-as-general-counsel 2026-06-17T19:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-silica-nanoparticles-eradicate-aggressive-prostate-cancer-in-mice-by-triggering-ferroptosis-and-immune-activation 2026-06-17T19:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-silica-nanoparticles-eradicate-aggressive-prostate-cancer-in-mice-by-triggering-ferroptosis-and-immune-activation 2026-06-17T19:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/j-pharma-and-uniphar-advance-first-in-class-lat1-inhibitor-nanvuranlat-into-global-phase-3-trial-for-biliary-tract-cancer 2026-06-17T19:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-pharma-and-uniphar-advance-first-in-class-lat1-inhibitor-nanvuranlat-into-global-phase-3-trial-for-biliary-tract-cancer 2026-06-17T19:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-moores-cancer-center-secures-25-million-nci-grant-renewal-strengthening-clinical-trial-infrastructure 2026-06-17T19:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-moores-cancer-center-secures-25-million-nci-grant-renewal-strengthening-clinical-trial-infrastructure 2026-06-17T19:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/jeremy-clarkson-reveals-aggressive-prostate-cancer-diagnosis-treatment-complications-on-clarkson-s-farm 2026-06-17T19:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeremy-clarkson-reveals-aggressive-prostate-cancer-diagnosis-treatment-complications-on-clarkson-s-farm 2026-06-17T19:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/bayfield-county-seeks-ems-support-as-missed-ambulance-calls-surge-83-in-2025 2026-06-17T19:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayfield-county-seeks-ems-support-as-missed-ambulance-calls-surge-83-in-2025 2026-06-17T19:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/how-170000-pakistani-genomes-could-transform-drug-development 2026-06-17T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-170000-pakistani-genomes-could-transform-drug-development 2026-06-17T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/gustave-roussy-and-the-lancet-launch-annual-lecture-series-on-cancer-breakthroughs 2026-06-17T18:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gustave-roussy-and-the-lancet-launch-annual-lecture-series-on-cancer-breakthroughs 2026-06-17T18:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-director-buys-25000-shares-as-taletrectinib-gains-global-regulatory-momentum 2026-06-17T18:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-director-buys-25000-shares-as-taletrectinib-gains-global-regulatory-momentum 2026-06-17T18:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/platelet-rich-plasma-market-poised-to-reach-1-4-billion-by-2036-as-regulatory-standardization-and-clinical-validation-drive-growth 2026-06-17T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/platelet-rich-plasma-market-poised-to-reach-1-4-billion-by-2036-as-regulatory-standardization-and-clinical-validation-drive-growth 2026-06-17T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-supply-group-launches-first-of-its-kind-network-connecting-wellness-clinics-to-clinical-trial-recruitment 2026-06-17T17:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolic-supply-group-launches-first-of-its-kind-network-connecting-wellness-clinics-to-clinical-trial-recruitment 2026-06-17T17:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/means-plus-function-claims-a-middle-ground-patent-strategy-for-biologics-after-amgen-v-sanofi 2026-06-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/means-plus-function-claims-a-middle-ground-patent-strategy-for-biologics-after-amgen-v-sanofi 2026-06-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-researchers-uncover-trem2-lam-macrophage-mechanism-driving-liver-cancer-immunotherapy-resistance 2026-06-17T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuhk-researchers-uncover-trem2-lam-macrophage-mechanism-driving-liver-cancer-immunotherapy-resistance 2026-06-17T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-reduced-post-treatment-monitoring-for-bms-s-breyanzi-car-t-therapy 2026-06-17T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-reduced-post-treatment-monitoring-for-bms-s-breyanzi-car-t-therapy 2026-06-17T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-and-abcellera-forge-up-to-4-billion-t-cell-engager-alliance-for-solid-tumors 2026-06-17T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-and-abcellera-forge-up-to-4-billion-t-cell-engager-alliance-for-solid-tumors 2026-06-17T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-draft-guidance-reshapes-ai-medical-device-safety-with-focus-on-model-drift-bias-and-data-poisoning 2026-06-17T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-draft-guidance-reshapes-ai-medical-device-safety-with-focus-on-model-drift-bias-and-data-poisoning 2026-06-17T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/ananda-pharma-publishes-clean-phase-i-safety-data-for-mrx1-cbd-oral-solution-paving-way-for-phase-ii-pain-trials 2026-06-17T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ananda-pharma-publishes-clean-phase-i-safety-data-for-mrx1-cbd-oral-solution-paving-way-for-phase-ii-pain-trials 2026-06-17T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/sysmex-launches-hiscltm-platform-for-rapid-scalable-alzheimer-s-blood-testing-with-17-minute-results 2026-06-17T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sysmex-launches-hiscltm-platform-for-rapid-scalable-alzheimer-s-blood-testing-with-17-minute-results 2026-06-17T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/ct-based-vmd-biomarker-predicts-gastric-cancer-survival-offering-path-to-personalized-treatment 2026-06-17T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ct-based-vmd-biomarker-predicts-gastric-cancer-survival-offering-path-to-personalized-treatment 2026-06-17T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-launches-700-million-behavioral-health-initiative-targeting-homelessness-and-addiction-including-new-streets-grant-program 2026-06-17T16:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-launches-700-million-behavioral-health-initiative-targeting-homelessness-and-addiction-including-new-streets-grant-program 2026-06-17T16:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/cerebral-organoid-model-reveals-how-ebola-virus-persists-in-the-brain-for-months 2026-06-17T16:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerebral-organoid-model-reveals-how-ebola-virus-persists-in-the-brain-for-months 2026-06-17T16:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-advances-dual-track-strategy-with-veterinary-and-human-clinical-trials-oral-peptide-ambitions 2026-06-17T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gelteq-advances-dual-track-strategy-with-veterinary-and-human-clinical-trials-oral-peptide-ambitions 2026-06-17T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/overdose-deaths-surge-among-australians-over-50-driven-by-prescription-drug-combinations 2026-06-17T15:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/overdose-deaths-surge-among-australians-over-50-driven-by-prescription-drug-combinations 2026-06-17T15:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/rewiring-pediatric-oncology-why-better-connections-are-needed-to-turn-discoveries-into-medicines 2026-06-17T15:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rewiring-pediatric-oncology-why-better-connections-are-needed-to-turn-discoveries-into-medicines 2026-06-17T15:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/isaaa-hosts-agbiotech-boot-camp-for-philippine-senior-high-school-students-and-teachers 2026-06-17T15:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isaaa-hosts-agbiotech-boot-camp-for-philippine-senior-high-school-students-and-teachers 2026-06-17T15:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/a-race-against-blindness-commits-1-million-to-advance-gene-agnostic-therapies-for-inherited-retinal-diseases 2026-06-17T15:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-race-against-blindness-commits-1-million-to-advance-gene-agnostic-therapies-for-inherited-retinal-diseases 2026-06-17T15:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/from-village-tragedy-to-un-advisor-abdoulaye-djimde-s-fight-against-malaria 2026-06-17T15:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-village-tragedy-to-un-advisor-abdoulaye-djimde-s-fight-against-malaria 2026-06-17T15:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/two-step-growth-factor-treatment-unlocks-hidden-regenerative-capacity-in-mammals 2026-06-17T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-step-growth-factor-treatment-unlocks-hidden-regenerative-capacity-in-mammals 2026-06-17T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/10x-genomics-and-lausanne-university-hospital-launch-multi-year-collaboration-to-advance-single-cell-and-spatial-diagnostics-in-oncology 2026-06-17T14:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10x-genomics-and-lausanne-university-hospital-launch-multi-year-collaboration-to-advance-single-cell-and-spatial-diagnostics-in-oncology 2026-06-17T14:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/step-pharma-advances-first-in-class-ctps1-inhibitor-dencatistat-into-phase-2-trial-for-essential-thrombocythaemia 2026-06-17T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/step-pharma-advances-first-in-class-ctps1-inhibitor-dencatistat-into-phase-2-trial-for-essential-thrombocythaemia 2026-06-17T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-reports-solid-q1-fy2026-results-secures-first-approval-for-narcolepsy-drug-orzeyful-in-china 2026-06-17T14:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-reports-solid-q1-fy2026-results-secures-first-approval-for-narcolepsy-drug-orzeyful-in-china 2026-06-17T14:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-to-host-science-day-investor-event-highlighting-mrna-platform-expansion-with-ai-and-robotics 2026-06-17T14:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-to-host-science-day-investor-event-highlighting-mrna-platform-expansion-with-ai-and-robotics 2026-06-17T14:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/nectin-therapeutics-first-in-class-anti-cd155-antibody-ntx1088-shows-promise-in-phase-1-combo-trial-at-asco-2026 2026-06-17T14:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nectin-therapeutics-first-in-class-anti-cd155-antibody-ntx1088-shows-promise-in-phase-1-combo-trial-at-asco-2026 2026-06-17T14:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-biotherapeutics-secures-fda-orphan-drug-designation-for-autologous-islet-transplantation-to-prevent-post-pancreatectomy-diabetes 2026-06-17T13:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-biotherapeutics-secures-fda-orphan-drug-designation-for-autologous-islet-transplantation-to-prevent-post-pancreatectomy-diabetes 2026-06-17T13:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/russia-registers-first-efanesoctocog-alfa-drug-for-haemophilia-a-as-nanolek-secures-eaeu-rights-to-china-s-armocibat 2026-06-17T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-registers-first-efanesoctocog-alfa-drug-for-haemophilia-a-as-nanolek-secures-eaeu-rights-to-china-s-armocibat 2026-06-17T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/deciphera-doses-first-patient-in-pivotal-phase-3-intrepid-study-of-sapablursen-in-polycythemia-vera 2026-06-17T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deciphera-doses-first-patient-in-pivotal-phase-3-intrepid-study-of-sapablursen-in-polycythemia-vera 2026-06-17T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/sedana-medical-s-nda-for-inhaled-isoflurane-sedation-accepted-by-fda-for-review 2026-06-17T13:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sedana-medical-s-nda-for-inhaled-isoflurane-sedation-accepted-by-fda-for-review 2026-06-17T13:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-elevates-ceo-yujiro-s-hata-to-chairman-as-precision-oncology-pipeline-advances-toward-commercialization 2026-06-17T13:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-elevates-ceo-yujiro-s-hata-to-chairman-as-precision-oncology-pipeline-advances-toward-commercialization 2026-06-17T13:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/island-pharmaceuticals-receives-fda-orphan-drug-designation-for-galidesivir-in-marburg-virus-post-exposure-prophylaxis 2026-06-17T11:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/island-pharmaceuticals-receives-fda-orphan-drug-designation-for-galidesivir-in-marburg-virus-post-exposure-prophylaxis 2026-06-17T11:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/bap1-mediated-deubiquitination-governs-treg-immune-tolerance-and-anti-tumor-immunity-via-ferroptosis-control 2026-06-17T11:47:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bap1-mediated-deubiquitination-governs-treg-immune-tolerance-and-anti-tumor-immunity-via-ferroptosis-control 2026-06-17T11:47:40+00:00 hourly 0.9 https://trial.medpath.com/news/vedana-therapeutics-launches-with-46m-series-a-to-develop-next-generation-pacap-targeting-migraine-therapies 2026-06-17T11:47:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vedana-therapeutics-launches-with-46m-series-a-to-develop-next-generation-pacap-targeting-migraine-therapies 2026-06-17T11:47:39+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-translational-research-gap-dr-reddy-s-whitepaper-maps-path-from-pharmacy-of-the-world-to-global-discovery-hub 2026-06-17T11:46:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-translational-research-gap-dr-reddy-s-whitepaper-maps-path-from-pharmacy-of-the-world-to-global-discovery-hub 2026-06-17T11:46:35+00:00 hourly 0.9 https://trial.medpath.com/news/gesynta-pharma-reaches-50-randomization-milestone-in-phase-2-nova-trial-of-non-hormonal-endometriosis-drug-vipoglanstat 2026-06-17T11:46:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gesynta-pharma-reaches-50-randomization-milestone-in-phase-2-nova-trial-of-non-hormonal-endometriosis-drug-vipoglanstat 2026-06-17T11:46:01+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-researchers-discover-a-hidden-kidney-pathway-for-water-regulation-opening-new-avenues-for-pkd-treatment 2026-06-17T11:45:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-researchers-discover-a-hidden-kidney-pathway-for-water-regulation-opening-new-avenues-for-pkd-treatment 2026-06-17T11:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-gap-90-of-clinicians-say-spiritual-care-is-essential-in-cancer-yet-few-routinely-screen-for-it 2026-06-17T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-gap-90-of-clinicians-say-spiritual-care-is-essential-in-cancer-yet-few-routinely-screen-for-it 2026-06-17T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rextovy-a-new-over-the-counter-naloxone-nasal-spray-expanding-access-to-opioid-overdose-reversal 2026-06-17T11:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-rextovy-a-new-over-the-counter-naloxone-nasal-spray-expanding-access-to-opioid-overdose-reversal 2026-06-17T11:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/norway-s-crown-princess-mette-marit-undergoes-successful-lung-transplant-for-pulmonary-fibrosis 2026-06-17T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norway-s-crown-princess-mette-marit-undergoes-successful-lung-transplant-for-pulmonary-fibrosis 2026-06-17T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-pharma-at-a-crossroads-us-pressure-and-china-s-rise-reshape-competitive-landscape 2026-06-17T10:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-pharma-at-a-crossroads-us-pressure-and-china-s-rise-reshape-competitive-landscape 2026-06-17T10:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-reveals-silent-prion-transmission-in-chronic-wasting-disease-raising-cross-species-concerns 2026-06-17T10:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-reveals-silent-prion-transmission-in-chronic-wasting-disease-raising-cross-species-concerns 2026-06-17T10:07:18+00:00 hourly 0.9